MeSH term
Frequency | Condition_Probility | Acute Disease | 32 | 1.0 |
Adult | 754 | 1.0 |
Comparative Study | 288 | 1.0 |
Humans | 2405 | 1.0 |
Patient Selection | 2 | 1.0 |
Prevalence | 12 | 0.0 |
World Health | 2 | 3.0 |
Immunohistochemistry | 88 | 0.0 |
Prognosis | 39 | 0.0 |
Recurrence | 31 | 2.0 |
Time Factors | 109 | 1.0 |
*Adaptation, Physiological | 2 | 3.0 |
Adolescent | 207 | 1.0 |
Antigens, CD31/metabolism | 4 | 5.0 |
Biological Markers/analysis | 30 | 3.0 |
Endothelium, Vascular/metabolism/pathology | 4 | 7.0 |
Female | 985 | 1.0 |
Fetal Blood/metabolism | 2 | 3.0 |
Homeostasis | 3 | 0.0 |
Models, Biological | 18 | 0.0 |
Pregnancy | 62 | 1.0 |
Research Support, Non-U.S. Gov't | 1202 | 0.0 |
Vascular Endothelial Growth Factor A/metabolism | 3 | 2.0 |
History, 19th Century | 2 | 6.0 |
History, 20th Century | 5 | 3.0 |
Binding Sites | 105 | 1.0 |
Exons | 21 | 0.0 |
Factor VIII/metabolism | 49 | 53.0 |
Heterozygote | 26 | 0.0 |
Middle Aged | 704 | 1.0 |
*Mutation, Missense | 10 | 1.0 |
Sequence Analysis, DNA | 11 | 0.0 |
von Willebrand Factor/*genetics | 88 | 88.0 |
Aged | 427 | 1.0 |
Biological Markers/blood | 104 | 7.0 |
Inflammation | 6 | 1.0 |
Interleukin-1/*blood | 2 | 3.0 |
Interleukin-6/*blood | 2 | 0.0 |
Male | 958 | 1.0 |
Myocardial Infarction/*blood/drug therapy/physiopathology | 2 | 100.0 |
von Willebrand Factor/*metabolism | 265 | 94.0 |
Alanine Transaminase/blood | 4 | 2.0 |
Aspartate Aminotransferases/blood | 4 | 3.0 |
Factor VIII/analysis | 46 | 45.0 |
Gastrointestinal Hemorrhage/etiology | 2 | 28.0 |
Partial Thromboplastin Time | 25 | 12.0 |
Platelet Count | 61 | 13.0 |
von Willebrand Factor/analysis | 226 | 71.0 |
*Blood Coagulation | 36 | 16.0 |
Blood Coagulation Factors/metabolism | 11 | 20.0 |
Blood Coagulation Tests | 51 | 25.0 |
Case-Control Studies | 84 | 1.0 |
*Hemostasis | 54 | 41.0 |
Intermittent Claudication/*blood | 2 | 100.0 |
Peripheral Vascular Diseases/blood | 3 | 100.0 |
Actins/analysis | 4 | 2.0 |
Bone Marrow/pathology | 2 | 0.0 |
Endothelial Growth Factors/analysis | 2 | 2.0 |
Lymphokines/analysis | 2 | 2.0 |
Neoplasm Invasiveness | 2 | 0.0 |
Vascular Endothelial Growth Factor A | 28 | 0.0 |
Vascular Endothelial Growth Factors | 28 | 0.0 |
Blood Platelets/*physiology | 50 | 29.0 |
Collagen/*pharmacology | 3 | 11.0 |
Phosphorylation | 16 | 0.0 |
*Platelet Activation | 24 | 17.0 |
Platelet Membrane Glycoproteins/*physiology | 14 | 43.0 |
Stress, Mechanical | 83 | 29.0 |
Thrombosis/etiology | 14 | 22.0 |
von Willebrand Factor/*pharmacology | 8 | 100.0 |
Blood Pressure/drug effects | 11 | 1.0 |
Cross-Sectional Studies | 41 | 3.0 |
Electrocardiography | 6 | 1.0 |
Hematocrit | 20 | 5.0 |
Regression Analysis | 32 | 2.0 |
Single-Blind Method | 6 | 2.0 |
Treatment Outcome | 44 | 1.0 |
von Willebrand Factor/*drug effects/metabolism | 5 | 100.0 |
von Willebrand Factor/genetics/*metabolism | 16 | 94.0 |
Amino Acid Sequence | 130 | 0.0 |
Antibody Formation | 3 | 0.0 |
Antibody Specificity | 20 | 1.0 |
Binding Sites/immunology | 2 | 3.0 |
Factor VIII/*immunology | 8 | 42.0 |
Precipitin Tests | 9 | 0.0 |
Recombinant Proteins/immunology | 6 | 1.0 |
Animals | 340 | 0.0 |
Dogs | 25 | 2.0 |
Drug Evaluation, Preclinical | 6 | 3.0 |
Hemophilia A/drug therapy | 5 | 71.0 |
Protein Engineering | 2 | 2.0 |
Protein Structure, Tertiary | 39 | 0.0 |
*Sequence Deletion | 5 | 1.0 |
Dimerization | 33 | 2.0 |
Disease Progression | 18 | 0.0 |
Metalloendopeptidases/blood/*deficiency | 3 | 60.0 |
von Willebrand Factor/metabolism | 195 | 72.0 |
Blood Glucose/metabolism | 5 | 0.0 |
Blood Pressure | 26 | 4.0 |
Child | 142 | 1.0 |
Child, Preschool | 100 | 1.0 |
Diabetes Mellitus, Type 1/blood/*physiopathology | 3 | 7.0 |
Endothelium, Vascular/*physiopathology | 42 | 46.0 |
Hemoglobin A, Glycosylated/metabolism | 2 | 1.0 |
Homocysteine/blood | 7 | 4.0 |
Homocystine/blood | 2 | 28.0 |
Reference Values | 93 | 2.0 |
Triglycerides/blood | 16 | 1.0 |
*Vasodilation | 4 | 28.0 |
Chronic Disease | 28 | 1.0 |
*Hematopoietic Stem Cell Transplantation | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 444 | 0.0 |
Skin/pathology | 2 | 0.0 |
*Cryopreservation | 3 | 4.0 |
Endothelium/cytology | 4 | 10.0 |
In Vitro | 98 | 1.0 |
Liver Transplantation/*physiology | 2 | 10.0 |
Platelet Activation/drug effects/physiology | 2 | 25.0 |
Platelet Adhesiveness/drug effects/*physiology | 5 | 62.0 |
Rats | 29 | 0.0 |
Rats, Sprague-Dawley | 4 | 0.0 |
Temperature | 14 | 1.0 |
Genotype | 32 | 0.0 |
Glycoproteins/genetics | 2 | 2.0 |
Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors | 2 | 10.0 |
Polymorphism, Genetic/genetics | 6 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 19 | 0.0 |
Risk Assessment | 7 | 0.0 |
Antibodies, Monoclonal | 63 | 2.0 |
Blood Platelets/cytology | 3 | 12.0 |
Cell Adhesion | 28 | 2.0 |
Enzyme-Linked Immunosorbent Assay | 95 | 2.0 |
Kinetics | 94 | 1.0 |
Ligands | 19 | 0.0 |
Microspheres | 10 | 5.0 |
Mutation | 51 | 0.0 |
*Platelet Aggregation | 39 | 45.0 |
*Platelet Membrane Glycoproteins | 26 | 61.0 |
Protein Binding | 153 | 1.0 |
Recombinant Proteins/metabolism | 27 | 1.0 |
von Willebrand Factor/*chemistry | 20 | 95.0 |
*Plasma Exchange | 4 | 17.0 |
*Platelet Transfusion | 4 | 16.0 |
Purpura, Thrombocytopenic/*therapy | 2 | 100.0 |
Blood Coagulation/*physiology | 12 | 10.0 |
Blood Coagulation Factors/*physiology | 16 | 69.0 |
Factor VIII/physiology | 7 | 77.0 |
Fibrinogen/physiology | 5 | 33.0 |
Fibrinolysis/physiology | 9 | 20.0 |
Hemostasis/*physiology | 15 | 27.0 |
Polymers | 8 | 7.0 |
Thrombin/physiology | 7 | 20.0 |
Thrombosis/*physiopathology | 2 | 25.0 |
Thrombospondins/physiology | 2 | 33.0 |
Vitronectin/physiology | 2 | 33.0 |
von Willebrand Factor/physiology | 23 | 85.0 |
Antigens/analysis | 44 | 32.0 |
Antigens, CD34/analysis | 12 | 1.0 |
Neovascularization, Pathologic/*pathology | 6 | 5.0 |
Observer Variation | 3 | 2.0 |
Survival Analysis | 8 | 0.0 |
Blood Coagulation Factors/analysis | 23 | 38.0 |
Blood Proteins/analysis | 12 | 7.0 |
Diabetes Complications | 2 | 1.0 |
Fibrinogen/analysis | 52 | 29.0 |
Inflammation/*blood | 3 | 7.0 |
Coronary Disease/*etiology | 2 | 7.0 |
Endothelium, Vascular/physiopathology | 4 | 11.0 |
Nitric Oxide/metabolism | 6 | 3.0 |
Polymorphism, Genetic | 22 | 0.0 |
Random Allocation | 2 | 0.0 |
Risk | 9 | 1.0 |
Fibrin Fibrinogen Degradation Products/*metabolism | 5 | 23.0 |
Antibodies, Antiphospholipid/*blood | 3 | 13.0 |
Carotid Arteries/*pathology | 2 | 25.0 |
Homocysteine/*blood | 11 | 4.0 |
Predictive Value of Tests | 35 | 1.0 |
Sex Characteristics | 9 | 1.0 |
Tunica Intima/*pathology | 2 | 10.0 |
Neovascularization, Pathologic/pathology | 4 | 6.0 |
von Willebrand Factor/analysis/metabolism | 8 | 88.0 |
*Amino Acid Substitution | 4 | 4.0 |
Antibodies, Monoclonal/immunology | 50 | 3.0 |
CHO Cells | 29 | 1.0 |
Consensus Sequence | 2 | 0.0 |
Cricetulus | 6 | 1.0 |
Gene Frequency | 9 | 0.0 |
Hamsters | 43 | 1.0 |
Japan | 9 | 0.0 |
Leucine | 3 | 6.0 |
Peptide Fragments/immunology | 7 | 3.0 |
Platelet Aggregation/drug effects | 89 | 41.0 |
Point Mutation | 31 | 1.0 |
*Polymorphism, Genetic | 21 | 0.0 |
Protein Conformation | 71 | 2.0 |
Protein Subunits | 3 | 0.0 |
Ristocetin/pharmacology | 116 | 90.0 |
Hemolytic-Uremic Syndrome/blood/*enzymology | 2 | 66.0 |
Hemorheology | 16 | 48.0 |
Metalloendopeptidases/*deficiency | 3 | 60.0 |
Purpura, Thrombotic Thrombocytopenic/blood/*enzymology | 2 | 100.0 |
Desmopressin/administration & dosage/pharmacology | 2 | 66.0 |
Hemorrhage/drug therapy/etiology | 3 | 100.0 |
Biopsy | 10 | 0.0 |
Endothelium, Vascular/chemistry | 5 | 8.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 67 | 0.0 |
Antibodies, Anticardiolipin/blood | 2 | 7.0 |
Biological Markers | 61 | 3.0 |
C-Reactive Protein/metabolism | 6 | 2.0 |
E-Selectin/blood | 16 | 28.0 |
Fibrin Fibrinogen Degradation Products/metabolism | 16 | 18.0 |
Intercellular Adhesion Molecule-1/blood | 19 | 23.0 |
Interleukin-6/blood | 12 | 2.0 |
Plasminogen Activator Inhibitor 1/blood | 33 | 28.0 |
Receptors, Interleukin-2/blood | 4 | 5.0 |
Coronary Artery Bypass/*adverse effects | 3 | 25.0 |
Metalloendopeptidases/blood | 2 | 28.0 |
Platelet Aggregation | 81 | 46.0 |
Risk Factors | 125 | 2.0 |
Immunoelectrophoresis | 9 | 3.0 |
Autoantibodies/*analysis | 5 | 2.0 |
Guinea Pigs | 7 | 0.0 |
Immunoglobulin A/analysis | 3 | 1.0 |
Retrospective Studies | 29 | 0.0 |
Sensitivity and Specificity | 40 | 1.0 |
Immunoglobulin G/chemistry | 3 | 13.0 |
Molecular Sequence Data | 182 | 0.0 |
Rabbits | 32 | 1.0 |
Blood Platelets/physiology | 16 | 27.0 |
Macromolecular Substances | 103 | 5.0 |
Recombinant Proteins/chemistry | 7 | 2.0 |
Transfection | 54 | 0.0 |
Laboratory Techniques and Procedures | 3 | 10.0 |
Chemotherapy, Adjuvant | 2 | 0.0 |
Desmopressin/therapeutic use | 21 | 70.0 |
Factor VIII/therapeutic use | 10 | 66.0 |
Hemorrhage/prevention & control | 3 | 60.0 |
von Willebrand Factor/therapeutic use | 5 | 100.0 |
Algorithms | 3 | 0.0 |
Antigens, CD34/*metabolism | 2 | 1.0 |
Cells, Cultured | 173 | 1.0 |
Phenotype | 53 | 0.0 |
Endothelium, Vascular/metabolism/*pathology | 5 | 27.0 |
Blood Platelets/drug effects/*metabolism | 14 | 19.0 |
DNA/analysis | 8 | 0.0 |
Flow Cytometry | 51 | 0.0 |
P-Selectin/metabolism | 5 | 10.0 |
Platelet Glycoprotein GPIIb-IIIa Complex/metabolism | 14 | 35.0 |
Platelet Glycoprotein GPIb-IX Complex/genetics/*metabolism | 4 | 100.0 |
Platelet Membrane Glycoproteins/metabolism | 24 | 29.0 |
Blood Platelets/*cytology | 3 | 12.0 |
*Cell Adhesion | 6 | 3.0 |
Fibrinogen/metabolism | 51 | 25.0 |
Endothelin-1/*metabolism | 2 | 12.0 |
Endothelium, Vascular/metabolism/*physiopathology | 3 | 42.0 |
Nitric Oxide/*metabolism | 3 | 2.0 |
Aged, 80 and over | 99 | 1.0 |
Analysis of Variance | 33 | 1.0 |
Angina Pectoris/blood | 2 | 14.0 |
Coronary Angiography | 4 | 1.0 |
*Hemorheology | 11 | 39.0 |
Myocardial Infarction/blood | 5 | 14.0 |
Platelet Aggregation/*physiology | 11 | 44.0 |
Antibodies, Monoclonal/metabolism | 8 | 2.0 |
DNA, Complementary/metabolism | 3 | 0.0 |
Dose-Response Relationship, Drug | 58 | 0.0 |
Gastric Mucin/*chemistry | 2 | 100.0 |
Mice | 77 | 0.0 |
Mice, Inbred BALB C | 12 | 0.0 |
Peptide Mapping | 6 | 1.0 |
Peptides/chemistry | 2 | 0.0 |
Tumor Cells, Cultured | 15 | 0.0 |
Data Collection | 4 | 4.0 |
Hemorrhage/blood/etiology | 2 | 50.0 |
Incidence | 20 | 1.0 |
Registries | 2 | 0.0 |
Disease Models, Animal | 10 | 0.0 |
Factor VIII/drug effects/metabolism | 4 | 100.0 |
Infusions, Parenteral | 3 | 2.0 |
LDL-Receptor Related Protein 1 | 2 | 1.0 |
LDL-Receptor Related Protein-Associated Protein | 2 | 18.0 |
Mice, Knockout | 4 | 0.0 |
*Molecular Probe Techniques | 2 | 22.0 |
Structure-Activity Relationship | 56 | 1.0 |
von Willebrand Disease/*drug therapy/metabolism | 2 | 100.0 |
von Willebrand Factor/administration & dosage/*pharmacology | 2 | 100.0 |
Drug Combinations | 8 | 1.0 |
Drug Monitoring/methods | 3 | 11.0 |
Factor VIII/*administration & dosage/pharmacokinetics | 2 | 100.0 |
Perioperative Care/methods | 2 | 66.0 |
Sterilization | 2 | 28.0 |
von Willebrand Factor/*administration & dosage/pharmacokinetics | 2 | 100.0 |
Agglutination Tests | 3 | 6.0 |
Collagen/*metabolism | 47 | 30.0 |
Ristocetin | 13 | 100.0 |
von Willebrand Disease/classification/*diagnosis | 2 | 100.0 |
von Willebrand Factor/*analysis | 162 | 97.0 |
Family Health | 17 | 1.0 |
*Laboratory Techniques and Procedures | 2 | 16.0 |
Autoantibodies/blood | 4 | 2.0 |
Collagen/metabolism | 45 | 17.0 |
Diagnosis, Differential | 20 | 0.0 |
Enzyme-Linked Immunosorbent Assay/standards | 4 | 28.0 |
Molecular Probe Techniques/*standards | 3 | 100.0 |
Chromatography, Affinity | 18 | 2.0 |
von Willebrand Disease/classification/diagnosis | 2 | 100.0 |
von Willebrand Factor/chemistry/*physiology | 3 | 100.0 |
Heparin/metabolism | 11 | 8.0 |
Immunoblotting | 22 | 0.0 |
Peptide Fragments/metabolism | 19 | 5.0 |
Plasma/chemistry | 4 | 12.0 |
von Willebrand Factor/*analysis/chemistry | 3 | 100.0 |
Platelet Adhesiveness | 31 | 65.0 |
von Willebrand Factor/metabolism/*physiology | 10 | 100.0 |
Bleeding Time | 83 | 75.0 |
Cohort Studies | 12 | 0.0 |
Factor VIII/drug effects | 2 | 100.0 |
Prospective Studies | 80 | 1.0 |
Severity of Illness Index | 22 | 1.0 |
Blood Proteins/*analysis | 6 | 4.0 |
Cholesterol/blood | 20 | 1.0 |
Endothelium, Vascular/*drug effects/metabolism | 5 | 8.0 |
Hemodynamic Processes/drug effects | 4 | 2.0 |
Hemoglobins/analysis | 5 | 1.0 |
Liver Function Tests | 2 | 1.0 |
*Renal Dialysis/adverse effects | 2 | 9.0 |
Endothelium, Vascular/*chemistry/ultrastructure | 3 | 75.0 |
Microscopy, Immunoelectron | 12 | 2.0 |
Up-Regulation | 6 | 0.0 |
Blood Coagulation/drug effects | 8 | 7.0 |
Papio | 4 | 2.0 |
von Willebrand Factor/*immunology/metabolism | 6 | 100.0 |
Magnetic Resonance Imaging | 6 | 0.0 |
Endothelium, Vascular/cytology/pathology | 2 | 66.0 |
Plasminogen Activator Inhibitor 1/*blood | 9 | 29.0 |
Tunica Intima/pathology | 2 | 7.0 |
Adenosine Diphosphate/pharmacology | 27 | 23.0 |
Calcium/blood | 8 | 3.0 |
Collagen/pharmacology | 21 | 16.0 |
Cytoplasmic Granules/secretion | 4 | 30.0 |
Epinephrine/pharmacology | 13 | 14.0 |
Platelet Activation/drug effects | 17 | 28.0 |
Platelet Function Tests | 13 | 31.0 |
Hemostasis/drug effects | 12 | 36.0 |
Transplantation, Heterologous | 5 | 0.0 |
Cesarean Section | 2 | 3.0 |
Endothelin-1/*blood | 8 | 38.0 |
English Abstract | 144 | 1.0 |
Infant, Newborn | 24 | 0.0 |
Nitric Oxide/*blood | 4 | 15.0 |
Antigens, CD31/analysis | 9 | 10.0 |
Microcirculation | 13 | 5.0 |
Necrosis | 3 | 0.0 |
Blood Sedimentation | 4 | 2.0 |
Cell Adhesion Molecules/*blood | 10 | 16.0 |
Complement | 2 | 4.0 |
Lupus Erythematosus, Systemic/blood/physiopathology | 2 | 66.0 |
Antibiotics, Peptide/pharmacology | 8 | 29.0 |
Blood Platelets/metabolism | 53 | 28.0 |
Cell Line | 54 | 0.0 |
Disulfides | 7 | 7.0 |
Epitope Mapping | 5 | 1.0 |
Gene Deletion | 5 | 0.0 |
Immunoglobulin G/metabolism | 3 | 1.0 |
Models, Molecular | 24 | 0.0 |
Plasmids/metabolism | 3 | 0.0 |
Platelet Glycoprotein GPIb-IX Complex/*chemistry | 2 | 100.0 |
Tyrosine/chemistry | 2 | 1.0 |
von Willebrand Factor/*chemistry/*metabolism | 7 | 100.0 |
Anemia/etiology | 2 | 6.0 |
Hemostatics/*therapeutic use | 7 | 53.0 |
von Willebrand Disease/*complications/drug therapy | 4 | 100.0 |
Multivariate Analysis | 22 | 1.0 |
Protein Precursors/genetics/metabolism | 2 | 6.0 |
*Protein Processing, Post-Translational | 5 | 1.0 |
Thrombin/metabolism | 14 | 9.0 |
Adsorption | 11 | 7.0 |
Biocompatible Materials | 6 | 9.0 |
Blood | 4 | 2.0 |
Fibrinogen/*metabolism | 15 | 20.0 |
Fibronectins/*metabolism | 3 | 4.0 |
Microscopy, Electron, Scanning | 16 | 5.0 |
Bone Marrow Transplantation/*adverse effects | 12 | 24.0 |
Kidney/blood supply | 4 | 23.0 |
Metalloendopeptidases/*metabolism | 5 | 5.0 |
Syndrome | 22 | 1.0 |
Thrombosis | 3 | 50.0 |
Dithiothreitol/pharmacology | 4 | 4.0 |
Heparin/*metabolism | 9 | 10.0 |
Immunoglobulin G/blood | 6 | 2.0 |
von Willebrand Disease/*blood/classification | 6 | 100.0 |
von Willebrand Factor/drug effects/*metabolism | 2 | 100.0 |
Endothelial Growth Factors/metabolism | 4 | 2.0 |
Gene Therapy/*methods | 3 | 0.0 |
Genetic Vectors | 10 | 0.0 |
Lymphokines/metabolism | 3 | 1.0 |
Mice, Inbred C57BL | 7 | 0.0 |
Neovascularization, Pathologic/*metabolism | 4 | 3.0 |
Thrombospondin 1/metabolism | 2 | 18.0 |
Blood Platelets/enzymology/metabolism | 2 | 33.0 |
Cytoskeleton/metabolism | 6 | 2.0 |
Enzyme Activation | 13 | 0.0 |
Platelet Activation/*physiology | 10 | 17.0 |
Platelet Glycoprotein GPIb-IX Complex/metabolism | 35 | 66.0 |
Protein Transport | 2 | 0.0 |
Signal Transduction | 16 | 0.0 |
Embryonic and Fetal Development | 2 | 0.0 |
Gestational Age | 7 | 0.0 |
Image Processing, Computer-Assisted | 7 | 1.0 |
Immunoenzyme Techniques | 39 | 1.0 |
Pulmonary Alveoli/blood supply | 2 | 100.0 |
Thrombomodulin/metabolism | 6 | 20.0 |
Cardiovascular Diseases/*blood/etiology | 2 | 66.0 |
Cytokines/*blood | 5 | 1.0 |
Diabetes Mellitus, Type 1/*blood | 4 | 2.0 |
Tumor Necrosis Factor-alpha/analysis | 10 | 2.0 |
Vascular Cell Adhesion Molecule-1/blood | 15 | 27.0 |
Endothelial Cells/*immunology | 2 | 28.0 |
Follow-Up Studies | 50 | 1.0 |
Immunophenotyping | 6 | 0.0 |
Leukocytes/immunology | 2 | 1.0 |
von Willebrand Factor/immunology/*metabolism | 21 | 100.0 |
Cell Separation | 10 | 0.0 |
Glycoproteins/chemistry | 2 | 7.0 |
T-Lymphocytes/immunology | 3 | 0.0 |
Alprostadil/administration & dosage/*therapeutic use | 3 | 100.0 |
Double-Blind Method | 36 | 2.0 |
Infusions, Intravenous | 27 | 4.0 |
Vasodilator Agents/administration & dosage/*therapeutic use | 3 | 60.0 |
Microscopy, Electron | 43 | 2.0 |
Platelet Aggregation/physiology | 17 | 44.0 |
Immune Tolerance | 4 | 1.0 |
Immunotherapy | 2 | 0.0 |
Culture Techniques | 4 | 0.0 |
Extracellular Matrix/*metabolism | 3 | 3.0 |
Platelet Adhesiveness/physiology | 8 | 61.0 |
Body Composition | 2 | 0.0 |
Body Constitution | 2 | 1.0 |
C-Reactive Protein/analysis | 13 | 2.0 |
*Indians, North American | 2 | 6.0 |
*Insulin Resistance | 4 | 2.0 |
Phospholipases A/blood | 3 | 23.0 |
Enzyme-Linked Immunosorbent Assay/methods | 6 | 2.0 |
Factor VIII/*metabolism | 47 | 82.0 |
Reproducibility of Results | 13 | 0.0 |
von Willebrand Factor/*analysis/metabolism | 9 | 100.0 |
Cell Adhesion/genetics | 3 | 5.0 |
Mutation, Missense | 6 | 0.0 |
Protein Binding/genetics | 5 | 2.0 |
COS Cells | 20 | 0.0 |
Mutagenesis, Site-Directed | 27 | 0.0 |
von Willebrand Factor/chemistry/*genetics/secretion | 2 | 100.0 |
Autonomic Nervous System/physiopathology | 2 | 7.0 |
Neurologic Examination | 2 | 1.0 |
Skin Temperature | 3 | 8.0 |
Thrombomodulin/blood | 21 | 58.0 |
Vasodilation | 5 | 14.0 |
Coronary Disease/*blood | 5 | 7.0 |
Endothelium, Vascular/*metabolism/pathology | 5 | 14.0 |
Tissue Plasminogen Activator/blood | 50 | 49.0 |
Angiotensin-Converting Enzyme Inhibitors/*pharmacology/therapeutic use | 3 | 10.0 |
Enalapril/*pharmacology/therapeutic use | 2 | 33.0 |
Fibrinolysis/*drug effects | 15 | 23.0 |
Plasminogen Activator Inhibitor 1/analysis | 8 | 24.0 |
Sex Factors | 9 | 0.0 |
Tissue Plasminogen Activator/analysis | 14 | 35.0 |
Alleles | 37 | 0.0 |
Antigens/*analysis | 16 | 18.0 |
Factor VIII/*analysis | 27 | 84.0 |
Gene Expression | 23 | 0.0 |
Metabolic Clearance Rate | 6 | 1.0 |
von Willebrand Disease/*blood/classification/genetics | 2 | 100.0 |
Bernard-Soulier Syndrome/*genetics | 2 | 100.0 |
Crystallography, X-Ray | 7 | 0.0 |
Electrostatics | 3 | 2.0 |
Sequence Alignment | 20 | 0.0 |
Species Specificity | 13 | 0.0 |
Tandem Repeat Sequences/*genetics | 5 | 5.0 |
Comorbidity | 11 | 4.0 |
Hemostasis | 35 | 33.0 |
von Willebrand Factor/chemistry/genetics/*physiology | 2 | 100.0 |
Plasma | 11 | 17.0 |
Biopolymers | 18 | 15.0 |
DNA, Complementary/genetics | 5 | 0.0 |
Exocytosis | 5 | 6.0 |
Gene Expression Regulation | 12 | 0.0 |
Hemorrhage/physiopathology | 2 | 50.0 |
Hemostasis/physiology | 14 | 43.0 |
Mice, Transgenic | 5 | 0.0 |
Molecular Weight | 116 | 4.0 |
Organ Specificity | 4 | 0.0 |
P-Selectin/physiology | 2 | 25.0 |
Protein Processing, Post-Translational | 18 | 2.0 |
Recombinant Fusion Proteins/physiology | 3 | 1.0 |
Weibel-Palade Bodies/secretion | 2 | 100.0 |
Pedigree | 89 | 1.0 |
RNA, Messenger/genetics | 13 | 0.0 |
Disseminated Intravascular Coagulation/blood | 4 | 21.0 |
Endothelium, Vascular/pathology | 19 | 17.0 |
Platelet Membrane Glycoproteins/*metabolism | 66 | 61.0 |
Surface Properties | 19 | 9.0 |
Thrombosis/blood | 4 | 21.0 |
Age Distribution | 3 | 0.0 |
Age of Onset | 3 | 0.0 |
Hemorrhage/etiology | 5 | 23.0 |
Hemostatics/therapeutic use | 5 | 83.0 |
Lymphoproliferative Disorders/complications | 4 | 57.0 |
Myeloproliferative Disorders/complications | 2 | 50.0 |
Paraproteinemias/complications | 2 | 66.0 |
Antigens/*blood | 9 | 37.0 |
Factor VIII/immunology | 2 | 22.0 |
Antibodies, Monoclonal/isolation & purification/*pharmacology | 2 | 100.0 |
Drug Interactions | 11 | 0.0 |
Epitopes/chemistry/immunology | 2 | 4.0 |
Platelet Adhesiveness/*drug effects | 26 | 78.0 |
Platelet Aggregation Inhibitors/pharmacology | 20 | 31.0 |
Protein Binding/drug effects | 29 | 8.0 |
Vimentin/analysis | 4 | 1.0 |
Thrombin/*biosynthesis | 2 | 6.0 |
von Willebrand Factor/antagonists & inhibitors/*immunology | 2 | 100.0 |
Endothelins/*blood | 7 | 26.0 |
Hypertension/*blood | 7 | 11.0 |
Pregnancy Complications, Cardiovascular/*blood | 4 | 19.0 |
Blood Platelets/*drug effects/metabolism | 6 | 16.0 |
Factor IX/metabolism | 4 | 28.0 |
Integrins/metabolism | 4 | 2.0 |
Platelet Aggregation/*drug effects/physiology | 6 | 60.0 |
Blood Preservation/*methods | 3 | 13.0 |
Immunoglobulin G/analysis | 7 | 1.0 |
Practice Guidelines | 3 | 3.0 |
United States | 4 | 0.0 |
Endothelium, Vascular/*physiology | 25 | 18.0 |
P-Selectin/*blood | 14 | 42.0 |
Receptors, Collagen | 12 | 17.0 |
von Willebrand Factor/antagonists & inhibitors | 3 | 75.0 |
Platelet Glycoprotein GPIb-IX Complex/*metabolism | 35 | 79.0 |
Sequence Analysis, Protein | 3 | 1.0 |
Sequence Homology, Amino Acid | 13 | 0.0 |
Substrate Specificity | 8 | 0.0 |
von Willebrand Factor/chemistry/*metabolism | 23 | 92.0 |
Cercopithecus aethiops | 8 | 0.0 |
Codon/genetics | 5 | 1.0 |
Cystine/chemistry | 2 | 18.0 |
*Point Mutation | 24 | 1.0 |
Protein Denaturation | 4 | 1.0 |
Protein Folding | 6 | 1.0 |
Recombinant Fusion Proteins/chemistry/metabolism | 2 | 1.0 |
von Willebrand Disease/*blood/genetics | 10 | 100.0 |
Blood Protein Electrophoresis | 10 | 9.0 |
Calcium Chloride/pharmacology | 2 | 9.0 |
Enzyme Activation/drug effects | 2 | 0.0 |
Enzyme Inhibitors/pharmacology | 7 | 0.0 |
Hirudins/pharmacology | 2 | 10.0 |
Protein Precursors/*metabolism | 5 | 6.0 |
Recombinant Fusion Proteins/metabolism | 10 | 0.0 |
Disease Susceptibility | 5 | 0.0 |
Tissue Plasminogen Activator/*analysis | 8 | 50.0 |
*Mutation | 28 | 0.0 |
von Willebrand Disease/classification/*genetics | 11 | 100.0 |
Antigens, CD34/*biosynthesis | 3 | 6.0 |
Enzyme Precursors/metabolism | 4 | 2.0 |
Phospholipase C/metabolism | 2 | 0.0 |
Protein-Tyrosine Kinase/metabolism | 2 | 0.0 |
Tyrosine/metabolism | 4 | 0.0 |
APACHE | 2 | 3.0 |
E-Selectin/*blood | 12 | 44.0 |
Statistics, Nonparametric | 11 | 1.0 |
Femoral Artery/ultrasonography | 2 | 66.0 |
Lipids/blood | 19 | 2.0 |
CHO Cells/metabolism | 2 | 5.0 |
Disulfides/chemistry | 5 | 7.0 |
China/epidemiology | 2 | 1.0 |
Introns | 8 | 0.0 |
Polymorphism, Genetic/*genetics | 6 | 0.0 |
von Willebrand Factor/analysis/*genetics | 6 | 100.0 |
DNA Mutational Analysis | 22 | 0.0 |
Platelet Glycoprotein GPIb-IX Complex/*genetics/metabolism | 3 | 75.0 |
Cell Division | 12 | 0.0 |
Cell Survival | 6 | 0.0 |
Lipopolysaccharides/pharmacology | 5 | 0.0 |
Mice, Nude | 4 | 0.0 |
Neovascularization, Physiologic | 2 | 1.0 |
Plasmids | 15 | 1.0 |
*Gene Therapy | 3 | 0.0 |
Hemophilia A/*therapy | 3 | 33.0 |
Antibodies, Monoclonal/*chemistry | 2 | 5.0 |
Blotting, Western | 29 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 74 | 2.0 |
Hybridomas | 2 | 1.0 |
Immunochemistry | 5 | 2.0 |
Recombinant Proteins/isolation & purification | 2 | 4.0 |
Surface Plasmon Resonance | 4 | 2.0 |
Collagen/*physiology | 4 | 20.0 |
Platelet Glycoprotein GPIb-IX Complex/physiology | 5 | 83.0 |
Platelet Membrane Glycoproteins/physiology | 11 | 61.0 |
Antihypertensive Agents/pharmacology/*therapeutic use | 2 | 13.0 |
Endothelium, Vascular/drug effects | 2 | 3.0 |
*Binding Sites, Antibody | 3 | 8.0 |
Cell Membrane/metabolism | 7 | 0.0 |
Hemophilia A/*immunology | 4 | 22.0 |
Keratin/metabolism | 2 | 1.0 |
*Neovascularization, Pathologic | 7 | 1.0 |
Tumor Markers, Biological/*metabolism | 2 | 0.0 |
African Continental Ancestry Group | 8 | 2.0 |
Blood Glucose/analysis | 7 | 1.0 |
Epinephrine/blood | 3 | 2.0 |
European Continental Ancestry Group | 8 | 1.0 |
Heart Rate | 3 | 1.0 |
Hemodynamic Processes | 10 | 5.0 |
Insulin/blood | 8 | 1.0 |
Norepinephrine/blood | 2 | 1.0 |
Body Mass Index | 10 | 0.0 |
Smoking/adverse effects | 2 | 0.0 |
Thrombophilia/blood/*etiology | 3 | 33.0 |
Endothelin-1/metabolism | 3 | 15.0 |
Endothelium, Vascular/cytology/*drug effects/metabolism | 3 | 3.0 |
L-Lactate Dehydrogenase/metabolism | 2 | 1.0 |
Plasminogen Activator Inhibitor 1/metabolism | 8 | 17.0 |
Umbilical Veins/cytology | 15 | 5.0 |
Blood Platelets/*pathology | 2 | 13.0 |
Metalloendopeptidases | 2 | 28.0 |
Antigens, CD34 | 3 | 0.0 |
Cell Differentiation | 13 | 0.0 |
Cell Separation/methods | 3 | 1.0 |
Coculture Techniques | 4 | 0.0 |
Colony-Forming Units Assay | 3 | 0.0 |
Flow Cytometry/methods | 2 | 0.0 |
Immunohistochemistry/methods | 4 | 0.0 |
Microscopy, Phase-Contrast | 4 | 4.0 |
*Neovascularization, Physiologic | 2 | 1.0 |
Logistic Models | 12 | 1.0 |
Venous Thrombosis/*blood | 2 | 16.0 |
Blood Platelets/*chemistry | 7 | 18.0 |
Cell Membrane/chemistry | 4 | 3.0 |
Chromatography, Gel | 18 | 2.0 |
Chromatography, High Pressure Liquid | 9 | 0.0 |
Cross-Linking Reagents | 4 | 1.0 |
Spectrophotometry, Ultraviolet | 2 | 1.0 |
Antigens, CD/analysis | 6 | 0.0 |
Integrin beta3 | 2 | 4.0 |
P-Selectin/analysis | 5 | 25.0 |
Peptide Fragments/pharmacology | 13 | 5.0 |
Platelet Membrane Glycoproteins/analysis | 7 | 10.0 |
*Oxidative Stress | 3 | 1.0 |
Uremia/*complications | 2 | 20.0 |
Blood Loss, Surgical/*prevention & control | 9 | 52.0 |
*Coronary Artery Bypass | 5 | 6.0 |
Drug Administration Schedule | 7 | 0.0 |
Fibrinogen/drug effects/metabolism | 2 | 28.0 |
Intraoperative Care | 3 | 13.0 |
Postoperative Period | 8 | 2.0 |
Prothrombin Time | 11 | 10.0 |
Surgical Procedures, Elective | 4 | 18.0 |
von Willebrand Factor/drug effects/metabolism | 8 | 80.0 |
Amino Acid Substitution | 11 | 0.0 |
Factor VIII/*chemistry/*metabolism | 3 | 100.0 |
Mammals | 2 | 0.0 |
Protein Structure, Secondary | 7 | 0.0 |
Blood Platelets/chemistry/*ultrastructure | 3 | 100.0 |
Cell Size | 6 | 2.0 |
Membrane Glycoproteins/analysis | 3 | 1.0 |
Platelet Glycoprotein GPIIb-IIIa Complex/analysis | 4 | 16.0 |
Glucose Tolerance Test | 3 | 0.0 |
Thromboxane B2/biosynthesis | 4 | 17.0 |
Hematologic Tests | 3 | 8.0 |
Endothelial Growth Factors/*analysis | 3 | 1.0 |
Lymphokines/*analysis | 3 | 1.0 |
Age Factors | 19 | 0.0 |
Metalloendopeptidases/*blood | 5 | 35.0 |
Blood Platelets/drug effects/metabolism | 17 | 41.0 |
*Membrane Proteins | 3 | 0.0 |
Platelet Activation/*drug effects | 12 | 18.0 |
von Willebrand Factor/metabolism/*pharmacology | 5 | 100.0 |
Blood Coagulation/physiology | 5 | 8.0 |
Mutation/genetics | 8 | 0.0 |
Polymerase Chain Reaction | 69 | 0.0 |
Endothelial Growth Factors/*physiology | 2 | 2.0 |
Lymphokines/*physiology | 2 | 1.0 |
Nitric Oxide/blood | 4 | 19.0 |
Electrophoresis, Agar Gel | 41 | 8.0 |
Reference Standards | 12 | 5.0 |
von Willebrand Disease/*blood | 33 | 94.0 |
von Willebrand Factor/*analysis/chemistry/genetics | 2 | 100.0 |
Glycosylation | 11 | 1.0 |
Perfusion | 19 | 9.0 |
Platelet Glycoprotein GPIb-IX Complex/analysis | 3 | 17.0 |
Blood Viscosity | 16 | 41.0 |
Platelet Aggregation/*drug effects | 43 | 32.0 |
Platelet Aggregation Inhibitors/*pharmacology | 19 | 28.0 |
Thrombosis/*drug therapy | 2 | 28.0 |
von Willebrand Factor/chemistry/*genetics/metabolism | 6 | 85.0 |
Diabetes Mellitus/*blood | 3 | 3.0 |
Diabetes Mellitus, Type 1/blood | 2 | 6.0 |
Diabetes Mellitus, Type 2/blood | 3 | 8.0 |
Lipoproteins/blood | 6 | 1.0 |
Myocardial Infarction/*blood | 5 | 8.0 |
Odds Ratio | 5 | 0.0 |
Amino Acid Motifs | 3 | 0.0 |
Base Sequence | 110 | 0.0 |
Chromosome Mapping | 13 | 0.0 |
Cloning, Molecular | 30 | 0.0 |
Liver/*enzymology | 2 | 0.0 |
Protein Isoforms/genetics | 2 | 0.0 |
RNA, Messenger/biosynthesis | 3 | 0.0 |
Tissue Distribution | 5 | 0.0 |
Transcription, Genetic | 7 | 0.0 |
Endothelium, Vascular/*pathology | 25 | 40.0 |
Pulmonary Circulation | 3 | 11.0 |
Thrombomodulin/analysis | 9 | 32.0 |
*Angioplasty, Balloon | 2 | 14.0 |
Creatinine/metabolism | 2 | 2.0 |
Exertion | 3 | 4.0 |
Serum Albumin/metabolism | 4 | 2.0 |
Apoptosis | 3 | 0.0 |
Blood Transfusion | 13 | 7.0 |
Infant | 54 | 0.0 |
Cadaver | 4 | 1.0 |
Blood Coagulation Factors/*metabolism | 31 | 39.0 |
Linear Models | 9 | 1.0 |
Cell Lineage | 3 | 0.0 |
Endothelium, Vascular/*cytology/metabolism | 8 | 15.0 |
Extracellular Matrix Proteins/genetics | 2 | 3.0 |
Glycoproteins/biosynthesis/genetics | 2 | 10.0 |
Membrane Glycoproteins/genetics | 2 | 1.0 |
Receptors, Cell Surface/genetics | 2 | 1.0 |
Receptors, Vascular Endothelial Growth Factor | 2 | 0.0 |
Vascular Endothelial Growth Factor Receptor-3 | 3 | 5.0 |
Blood Platelets/*drug effects | 6 | 15.0 |
Endothelium, Vascular/*drug effects | 7 | 13.0 |
Leg/blood supply | 2 | 6.0 |
P-Selectin/blood | 18 | 29.0 |
Pancreatic Elastase/blood | 3 | 12.0 |
Thromboxane B2/blood | 8 | 20.0 |
Acetylcholine/pharmacology | 3 | 4.0 |
Administration, Oral | 5 | 0.0 |
Cross-Over Studies | 15 | 2.0 |
Heart Rate/drug effects | 2 | 0.0 |
Homocysteine/*blood/drug effects | 2 | 66.0 |
Laser-Doppler Flowmetry | 5 | 12.0 |
Nitroprusside/pharmacology | 6 | 8.0 |
Pressure | 2 | 1.0 |
Skin/blood supply | 5 | 8.0 |
Vasodilator Agents/pharmacology | 3 | 5.0 |
von Willebrand Factor/chemistry/genetics/*metabolism | 5 | 100.0 |
Calcimycin/pharmacology | 12 | 5.0 |
Ionophores/pharmacology | 5 | 3.0 |
von Willebrand Disease/*blood/drug therapy | 6 | 100.0 |
von Willebrand Factor/*antagonists & inhibitors/metabolism | 2 | 100.0 |
Lupus Erythematosus, Systemic/blood | 3 | 10.0 |
Purpura, Thrombotic Thrombocytopenic/*blood | 3 | 42.0 |
Remission Induction | 7 | 1.0 |
Chromatography, Ion Exchange | 6 | 1.0 |
Factor VIII/chemistry/*metabolism | 2 | 100.0 |
Half-Life | 9 | 1.0 |
alpha-Macroglobulins/analysis | 4 | 10.0 |
von Willebrand Factor/chemistry/metabolism | 3 | 100.0 |
Endothelium, Vascular/*drug effects/*physiopathology | 4 | 57.0 |
Heptanoic Acids/*therapeutic use | 2 | 8.0 |
*Kidney Transplantation | 6 | 1.0 |
Microcirculation/physiology | 5 | 15.0 |
Pilot Projects | 7 | 1.0 |
Pyrroles/*therapeutic use | 2 | 5.0 |
C-Reactive Protein/*analysis | 2 | 0.0 |
Endothelium, Vascular/physiology/*physiopathology | 3 | 60.0 |
Hemoglobin A, Glycosylated/analysis | 10 | 2.0 |
Inflammation/blood | 5 | 9.0 |
Peptide Fragments/analysis | 14 | 6.0 |
Protein Precursors/analysis | 4 | 9.0 |
Prothrombin/analysis | 9 | 12.0 |
Tissue Plasminogen Activator/*blood | 15 | 46.0 |
Tumor Necrosis Factor-alpha/*analysis | 2 | 0.0 |
Purpura, Thrombotic Thrombocytopenic/*drug therapy | 2 | 100.0 |
Binding Sites/genetics | 10 | 1.0 |
Binding, Competitive | 34 | 1.0 |
Endothelium, Vascular/*chemistry/cytology | 2 | 25.0 |
European Continental Ancestry Group/genetics | 4 | 0.0 |
Great Britain/epidemiology | 2 | 1.0 |
Promoter Regions (Genetics)/*genetics | 4 | 0.0 |
Fibrin/metabolism | 8 | 12.0 |
Rheology | 16 | 22.0 |
Thrombin/*pharmacology | 23 | 20.0 |
von Willebrand Factor/immunology/*physiology | 11 | 100.0 |
Inhibitory Concentration 50 | 2 | 0.0 |
von Willebrand Factor/antagonists & inhibitors/*metabolism | 4 | 100.0 |
Staining and Labeling | 7 | 1.0 |
Antithrombin III/analysis | 24 | 12.0 |
Fibrin Fibrinogen Degradation Products/analysis | 23 | 17.0 |
Peptide Hydrolases/analysis | 10 | 7.0 |
Tumor Markers, Biological/*blood | 4 | 0.0 |
Adenosine Triphosphate/secretion | 3 | 37.0 |
Materials Testing | 4 | 5.0 |
Platelet Adhesiveness/*physiology | 19 | 86.0 |
Thrombosis/blood/*etiology | 2 | 28.0 |
*Biocompatible Materials | 3 | 8.0 |
Endothelium, Vascular/immunology | 4 | 9.0 |
Inflammation Mediators/*blood | 3 | 6.0 |
Autoantibodies/*blood | 5 | 1.0 |
Blood Platelets/drug effects/*physiology | 11 | 26.0 |
Matched-Pair Analysis | 3 | 3.0 |
*Tetrahydroisoquinolines | 3 | 4.0 |
*Exercise | 5 | 3.0 |
Neutrophils/metabolism | 3 | 2.0 |
Thrombosis/*blood | 9 | 32.0 |
Blood Circulation/*drug effects | 2 | 33.0 |
Cholesterol/*blood | 2 | 0.0 |
Hemostasis/*drug effects | 20 | 30.0 |
Endothelium, Vascular/cytology/*immunology | 3 | 9.0 |
Lupus Coagulation Inhibitor/*blood | 3 | 23.0 |
Lupus Erythematosus, Systemic/blood/*immunology | 2 | 5.0 |
Frameshift Mutation | 2 | 0.0 |
Genes, Dominant | 12 | 1.0 |
Sequence Deletion | 10 | 0.0 |
von Willebrand Disease/*genetics | 56 | 98.0 |
von Willebrand Factor/*genetics/*metabolism | 5 | 71.0 |
Crotalid Venoms/pharmacology | 30 | 83.0 |
Epitope Mapping/*methods | 2 | 14.0 |
Peptide Library | 2 | 1.0 |
*Plasmapheresis | 4 | 13.0 |
Adenoviridae/genetics | 2 | 0.0 |
Gene Expression Profiling | 3 | 0.0 |
Cell Count | 6 | 0.0 |
Collagen | 14 | 8.0 |
Epoprostenol/*secretion | 2 | 100.0 |
Polystyrenes | 4 | 16.0 |
von Willebrand Factor/*secretion | 26 | 100.0 |
*Exercise Test | 2 | 5.0 |
Exertion/*physiology | 4 | 6.0 |
Intercellular Adhesion Molecule-1/*blood | 7 | 11.0 |
Smoking | 8 | 2.0 |
Vascular Cell Adhesion Molecule-1/*blood | 8 | 30.0 |
Coronary Disease/blood/*drug therapy | 2 | 25.0 |
Platelet Glycoprotein GPIIb-IIIa Complex | 3 | 60.0 |
*Stents | 2 | 3.0 |
Lipoproteins, HDL Cholesterol/blood | 10 | 1.0 |
Solubility | 26 | 1.0 |
Thrombomodulin/*blood | 14 | 53.0 |
Immunosuppressive Agents/therapeutic use | 3 | 1.0 |
Plasma Exchange | 9 | 42.0 |
Hemolytic-Uremic Syndrome/*blood/complications | 2 | 100.0 |
von Willebrand Factor/*physiology | 63 | 95.0 |
Antibodies/blood/*immunology | 2 | 20.0 |
Antigen-Antibody Reactions | 9 | 2.0 |
Factor VIII/*immunology/therapeutic use | 3 | 42.0 |
Hemophilia A/blood/*drug therapy/*immunology | 2 | 100.0 |
von Willebrand Factor/*immunology | 25 | 96.0 |
Antibodies/pharmacology | 2 | 0.0 |
Antibodies, Monoclonal/pharmacology | 13 | 1.0 |
Erythrocytes/*physiology | 3 | 6.0 |
Fetal Blood | 3 | 2.0 |
Immunoglobulins, Fab/pharmacology | 3 | 13.0 |
Leukocytes/*physiology | 2 | 3.0 |
*Platelet Function Tests | 4 | 66.0 |
Cyclosporine/*adverse effects/therapeutic use | 2 | 50.0 |
Endothelium, Vascular/*drug effects/physiology | 3 | 16.0 |
Endothelium, Vascular/cytology | 14 | 5.0 |
Lipoproteins/*blood | 7 | 1.0 |
*Renal Dialysis | 10 | 2.0 |
Thrombosis/complications | 2 | 22.0 |
Endothelial Growth Factors/*metabolism | 3 | 0.0 |
Immunologic Techniques | 6 | 1.0 |
Lymphokines/*metabolism | 3 | 0.0 |
Purpura, Thrombotic Thrombocytopenic/blood | 3 | 50.0 |
Peptidyl-Dipeptidase A/*blood | 4 | 3.0 |
Scleroderma, Systemic/*complications | 2 | 33.0 |
Antigens, CD34/metabolism | 5 | 1.0 |
Neovascularization, Physiologic/*physiology | 2 | 1.0 |
Stem Cells/*cytology/metabolism | 2 | 7.0 |
Cattle | 40 | 1.0 |
Extracellular Matrix/metabolism | 3 | 1.0 |
Fibronectins/metabolism | 13 | 7.0 |
Platelet Activation | 22 | 16.0 |
Folic Acid/*therapeutic use | 3 | 37.0 |
Nitrates/blood | 3 | 11.0 |
Nitrites/blood | 2 | 8.0 |
Regional Blood Flow | 7 | 5.0 |
Endothelium, Vascular/drug effects/*secretion | 2 | 100.0 |
*Exocytosis | 3 | 10.0 |
Thrombin/pharmacology | 44 | 19.0 |
Heterozygote Detection/*methods | 7 | 13.0 |
von Willebrand Disease/diagnosis/*genetics | 5 | 100.0 |
Blood Coagulation Tests/*instrumentation | 3 | 42.0 |
Calibration | 6 | 4.0 |
Membrane Proteins/metabolism | 3 | 0.0 |
Receptors, Cell Surface/metabolism | 12 | 2.0 |
von Willebrand Disease/blood/diagnosis | 2 | 100.0 |
Creatinine/blood | 8 | 2.0 |
Kidney Failure, Chronic/blood/*physiopathology/therapy | 2 | 50.0 |
Malondialdehyde/blood | 2 | 3.0 |
Renal Dialysis | 13 | 4.0 |
*Adaptor Proteins, Signal Transducing | 3 | 0.0 |
Blood Platelets/*metabolism/physiology | 6 | 54.0 |
Mice, Mutant Strains | 2 | 0.0 |
Phosphorylation/drug effects | 2 | 0.0 |
Signal Transduction/*drug effects | 3 | 0.0 |
von Willebrand Factor/pharmacology | 12 | 80.0 |
Heteroduplex Analysis | 2 | 2.0 |
Platelet Membrane Glycoproteins/genetics | 2 | 15.0 |
Antigens, Differentiation, Myelomonocytic/analysis | 3 | 0.0 |
*Apoptosis | 2 | 0.0 |
DNA Fragmentation | 2 | 0.0 |
In Situ Nick-End Labeling | 3 | 0.0 |
Macrophages/immunology/pathology | 2 | 6.0 |
Factor VII/*analysis | 5 | 27.0 |
Fibrinogen/*analysis | 14 | 32.0 |
Hemostasis/drug effects/*physiology | 5 | 71.0 |
Epitopes | 15 | 1.0 |
Atrial Fibrillation/*blood | 2 | 66.0 |
Exercise/*physiology | 7 | 1.0 |
ABO Blood-Group System | 7 | 11.0 |
Carbohydrate Sequence | 4 | 1.0 |
von Willebrand Factor/chemistry/immunology/metabolism | 3 | 100.0 |
Alprostadil/pharmacology | 2 | 7.0 |
Aspirin/pharmacology | 6 | 10.0 |
Blood Platelets/secretion | 3 | 50.0 |
Immunoglobulins, Fab/immunology | 6 | 5.0 |
Platelet Glycoprotein GPIb-IX Complex/*immunology | 2 | 100.0 |
Drug Stability | 2 | 0.0 |
Factor VIII/analysis/*standards | 2 | 100.0 |
Hemophilia A/blood/diagnosis | 2 | 100.0 |
World Health Organization | 3 | 3.0 |
Antibodies, Monoclonal/analysis | 2 | 2.0 |
Blood Platelets/*metabolism/ultrastructure | 3 | 27.0 |
Cell Adhesion/drug effects | 17 | 4.0 |
Cell Movement/drug effects | 4 | 1.0 |
L-Lactate Dehydrogenase/blood | 4 | 3.0 |
Thromboplastin/metabolism | 3 | 3.0 |
Bone Marrow Transplantation | 2 | 0.0 |
Electrophoresis, Agar Gel/*methods | 2 | 12.0 |
Leukocyte Count | 14 | 0.0 |
Light | 5 | 2.0 |
Methylene Blue/*pharmacology | 2 | 66.0 |
Injections, Intravenous | 8 | 1.0 |
*Health Policy | 2 | 5.0 |
Endothelium, Vascular/cytology/*metabolism | 10 | 5.0 |
Metalloendopeptidases/metabolism | 4 | 6.0 |
Hemophilia A/blood | 9 | 56.0 |
International Cooperation | 5 | 6.0 |
Specimen Handling | 2 | 2.0 |
von Willebrand Disease/blood | 25 | 100.0 |
von Willebrand Factor/analysis/*standards | 2 | 100.0 |
Blood Flow Velocity | 7 | 7.0 |
Blood Platelets/*metabolism | 63 | 22.0 |
Models, Chemical | 2 | 0.0 |
14-3-3 Proteins | 4 | 2.0 |
Microfilament Proteins/metabolism | 2 | 2.0 |
Receptors, Immunologic/metabolism | 2 | 1.0 |
Thrombosis/blood/etiology | 4 | 33.0 |
Blood Coagulation/*drug effects | 12 | 9.0 |
Fibrinolytic Agents/*therapeutic use | 3 | 12.0 |
*Thrombolytic Therapy | 2 | 9.0 |
Chi-Square Distribution | 3 | 0.0 |
Heart Ventricles | 2 | 3.0 |
Blood Platelets/chemistry/*metabolism | 3 | 37.0 |
*Peritoneal Dialysis | 3 | 5.0 |
Platelet Glycoprotein GPIIb-IIIa Complex/*metabolism | 6 | 20.0 |
Endothelium, Vascular/*cytology/secretion | 2 | 50.0 |
Platelet Adhesiveness/drug effects | 18 | 40.0 |
von Willebrand Factor/secretion | 6 | 75.0 |
Blood Pressure/physiology | 3 | 1.0 |
Factor IX/genetics | 2 | 9.0 |
Hemophilia A/*diagnosis/genetics | 4 | 36.0 |
Heterozygote Detection | 5 | 0.0 |
*Bleeding Time | 10 | 100.0 |
von Willebrand Factor/analysis/*immunology | 7 | 87.0 |
Endothelium/cytology/*metabolism | 3 | 27.0 |
Fibronectins/blood | 8 | 36.0 |
Alprostadil/*pharmacology | 2 | 18.0 |
Fibrosis | 2 | 1.0 |
Ki-67 Antigen | 2 | 0.0 |
Neovascularization, Physiologic/*drug effects | 2 | 2.0 |
Vasodilator Agents/*pharmacology | 2 | 4.0 |
Blood Platelets/chemistry/metabolism | 2 | 33.0 |
Platelet Aggregation Inhibitors/metabolism | 2 | 28.0 |
von Willebrand Disease/*blood/complications | 3 | 100.0 |
Desmopressin/administration & dosage | 7 | 53.0 |
Factor VIII/administration & dosage | 5 | 100.0 |
Hemorrhage | 3 | 25.0 |
Hemostatics/administration & dosage | 2 | 100.0 |
Variation (Genetics) | 8 | 0.0 |
Liver/metabolism | 3 | 0.0 |
Protein Biosynthesis | 3 | 0.0 |
Proteins/metabolism | 3 | 0.0 |
Blood Proteins/metabolism | 3 | 1.0 |
Endothelial Growth Factors/blood | 4 | 7.0 |
Lymphokines/blood | 4 | 7.0 |
P-Selectin/*metabolism | 5 | 23.0 |
Viscosity | 3 | 9.0 |
Constriction, Pathologic/blood | 3 | 75.0 |
Filtration | 5 | 10.0 |
Glutamic Acid | 4 | 5.0 |
Hemagglutinins/pharmacology | 11 | 100.0 |
Phenylalanine | 2 | 7.0 |
Platelet Glycoprotein GPIb-IX Complex/*chemistry/*metabolism | 2 | 100.0 |
Recombinant Proteins/chemistry/metabolism | 12 | 1.0 |
Mutagenesis | 10 | 0.0 |
Platelet Glycoprotein GPIb-IX Complex/chemistry/*metabolism | 8 | 72.0 |
Cell Movement/*physiology | 2 | 0.0 |
Collagen/chemistry | 2 | 11.0 |
Endothelium/*cytology/*physiology | 2 | 66.0 |
Umbilical Veins | 42 | 9.0 |
von Willebrand Factor/chemistry | 6 | 60.0 |
von Willebrand Disease/classification/genetics/*metabolism | 3 | 100.0 |
von Willebrand Factor/*chemistry/genetics | 3 | 100.0 |
Antithrombin III | 2 | 3.0 |
Cyclosporine/therapeutic use | 2 | 2.0 |
Peptide Hydrolases/blood | 2 | 4.0 |
Thromboxanes/*biosynthesis | 2 | 28.0 |
Desmopressin/diagnostic use | 7 | 70.0 |
Ristocetin/metabolism | 19 | 100.0 |
von Willebrand Disease/*diagnosis | 8 | 100.0 |
von Willebrand Factor/analysis/genetics/*metabolism | 3 | 100.0 |
Anticoagulants/*pharmacology | 2 | 2.0 |
Aspirin/*pharmacology | 8 | 18.0 |
Heparin/*pharmacology | 3 | 2.0 |
Cell Culture Techniques/methods | 4 | 1.0 |
Trypsin/*pharmacology | 4 | 44.0 |
Peptide Fragments/*blood | 3 | 3.0 |
Scleroderma, Systemic/*blood | 4 | 50.0 |
Homozygote | 16 | 0.0 |
Cell Culture Techniques | 6 | 1.0 |
Polymerase Chain Reaction/methods | 6 | 0.0 |
Umbilical Veins/cytology/*metabolism | 4 | 36.0 |
von Willebrand Factor/biosynthesis | 15 | 65.0 |
Biological Assay | 5 | 1.0 |
*Fibrinolysis | 19 | 14.0 |
Antithrombin III/*metabolism | 2 | 3.0 |
Blood Coagulation | 34 | 20.0 |
Peptide Hydrolases/*metabolism | 2 | 2.0 |
Arteriosclerosis/*blood/complications | 2 | 25.0 |
Diabetes Mellitus, Type 2/blood/*complications | 2 | 10.0 |
Blood Coagulation/*drug effects/physiology | 2 | 28.0 |
Exercise Test | 6 | 2.0 |
Fibrinolysis/*drug effects/physiology | 2 | 28.0 |
Probability | 5 | 0.0 |
Plasminogen Inactivators/metabolism | 2 | 12.0 |
Anticoagulants/*pharmacology/therapeutic use | 2 | 28.0 |
Hemorrhage/*drug therapy | 2 | 100.0 |
Italy/epidemiology | 2 | 0.0 |
Linkage (Genetics) | 8 | 0.0 |
Lung/metabolism | 2 | 1.0 |
Survival Rate | 10 | 0.0 |
Green Fluorescent Proteins | 2 | 0.0 |
*Transfection | 2 | 0.0 |
Fluorescent Antibody Technique | 31 | 1.0 |
Microfilaments/ultrastructure | 2 | 13.0 |
Microscopy, Fluorescence | 8 | 0.0 |
Tumor Necrosis Factor-alpha/pharmacology | 9 | 0.0 |
Cell Division/drug effects | 12 | 0.0 |
Endothelial Growth Factors/pharmacology | 2 | 1.0 |
Endothelium | 4 | 57.0 |
Fibroblast Growth Factor 2/pharmacology | 2 | 0.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology | 3 | 0.0 |
Insulin-Like Growth Factor I/pharmacology | 2 | 1.0 |
Lymphokines/pharmacology | 2 | 1.0 |
Peptides/pharmacology | 4 | 2.0 |
von Willebrand Factor/*biosynthesis | 10 | 90.0 |
Circular Dichroism | 4 | 0.0 |
Peptide Fragments/chemistry | 8 | 4.0 |
Albuminuria | 4 | 8.0 |
Anticholesteremic Agents/therapeutic use | 3 | 9.0 |
Anticoagulants/pharmacology | 2 | 2.0 |
Endothelin-1/blood | 6 | 35.0 |
Prothrombin/metabolism | 8 | 10.0 |
Thrombosis/metabolism | 3 | 25.0 |
Point Mutation/*genetics | 3 | 1.0 |
Platelet Glycoprotein GPIb-IX Complex/immunology/*metabolism | 3 | 75.0 |
von Willebrand Factor/antagonists & inhibitors/metabolism | 2 | 100.0 |
Haplotypes | 5 | 0.0 |
Minisatellite Repeats | 2 | 1.0 |
Polymorphism, Restriction Fragment Length | 13 | 0.0 |
Mass Screening/*methods | 2 | 3.0 |
Endothelium/*cytology | 3 | 14.0 |
Shock, Septic/*blood | 2 | 10.0 |
*Bone Marrow Cells | 4 | 1.0 |
Cell Line, Transformed | 4 | 0.0 |
*Endothelium, Vascular | 2 | 50.0 |
Swine | 32 | 2.0 |
*Transplantation, Heterologous | 4 | 5.0 |
Epitopes/immunology | 14 | 2.0 |
Genetic Predisposition to Disease | 7 | 0.0 |
Liposomes | 2 | 0.0 |
Platelet Adhesiveness/drug effects/physiology | 2 | 40.0 |
Platelet Aggregation Inhibitors/*pharmacology/therapeutic use | 3 | 60.0 |
von Willebrand Factor/*antagonists & inhibitors/immunology | 3 | 100.0 |
Angiogenesis Inhibitors/*pharmacology | 2 | 2.0 |
Fibrinolytic Agents/*pharmacology | 3 | 9.0 |
Mice, Inbred ICR | 2 | 0.0 |
Platelet Glycoprotein GPIb-IX Complex/*antagonists & inhibitors | 3 | 100.0 |
Thromboembolism/blood/etiology | 2 | 66.0 |
Thrombophilia/blood/etiology | 2 | 28.0 |
Venous Thrombosis/*blood/etiology | 2 | 66.0 |
Thrombocytopenia/*etiology | 3 | 18.0 |
Blood Coagulation Factors/*analysis | 29 | 35.0 |
Cell Adhesion Molecules/metabolism | 7 | 2.0 |
Endothelium, Vascular/*cytology/drug effects/metabolism | 4 | 20.0 |
Placenta/*blood supply | 3 | 18.0 |
Proliferating Cell Nuclear Antigen/metabolism | 3 | 1.0 |
Osmolar Concentration | 10 | 1.0 |
Erythrocyte Count | 2 | 2.0 |
Glycoproteins/blood | 7 | 12.0 |
Platelet Factor 4/analysis | 5 | 6.0 |
ABO Blood-Group System/*physiology | 3 | 75.0 |
Crotalid Venoms/metabolism | 9 | 69.0 |
Genes, Structural | 8 | 0.0 |
Introns/genetics | 2 | 0.0 |
*Protein Folding | 2 | 1.0 |
International Normalized Ratio | 2 | 6.0 |
Kidney Failure, Chronic/*blood/therapy | 7 | 12.0 |
*Peritoneal Dialysis, Continuous Ambulatory | 2 | 1.0 |
Factor VIII/analysis/*genetics | 2 | 100.0 |
*Family | 2 | 5.0 |
Fibrin Fibrinogen Degradation Products/*analysis | 5 | 10.0 |
Thrombosis/*etiology | 7 | 14.0 |
Alanine | 2 | 2.0 |
Crotalid Venoms/*metabolism | 2 | 100.0 |
von Willebrand Factor/*chemistry/metabolism | 6 | 66.0 |
*Platelet Aggregation/drug effects | 15 | 48.0 |
Desmopressin/pharmacology | 18 | 51.0 |
Hemostatics/pharmacology | 3 | 13.0 |
Platelet Aggregation/drug effects/physiology | 5 | 25.0 |
von Willebrand Disease/*genetics/metabolism | 5 | 100.0 |
Antibodies, Monoclonal/*pharmacology | 5 | 2.0 |
Immunoglobulins, Fab/*pharmacology | 2 | 33.0 |
Aspirin/therapeutic use | 3 | 7.0 |
Combined Modality Therapy | 3 | 0.0 |
Platelet Aggregation Inhibitors/therapeutic use | 3 | 10.0 |
Platelet Glycoprotein GPIb-IX Complex/immunology/metabolism | 2 | 100.0 |
Ristocetin/*pharmacology | 25 | 92.0 |
Australia | 2 | 1.0 |
von Willebrand Disease/blood/*diagnosis | 5 | 83.0 |
Blood Platelets/cytology/metabolism | 3 | 42.0 |
Filtration/methods | 2 | 28.0 |
Cell Adhesion Molecules | 2 | 3.0 |
Endothelium, Vascular/*metabolism/*physiopathology | 2 | 100.0 |
Antibodies/*immunology | 7 | 5.0 |
Blood Coagulation Tests/methods | 2 | 20.0 |
Hemophilia A/blood/*immunology | 3 | 60.0 |
Cytoplasm/metabolism | 3 | 0.0 |
Endothelium, Vascular/*metabolism | 32 | 12.0 |
Fluorescent Antibody Technique, Indirect | 7 | 0.0 |
Gene Therapy/methods | 2 | 2.0 |
Hemophilia A/therapy | 2 | 40.0 |
von Willebrand Factor/biosynthesis/genetics | 2 | 66.0 |
Adrenergic alpha-Antagonists/pharmacology | 4 | 22.0 |
Arachidonic Acid/pharmacology | 3 | 7.0 |
Calcium/metabolism | 16 | 1.0 |
Drug Synergism | 5 | 0.0 |
Serotonin/secretion | 5 | 20.0 |
Sympathomimetics/pharmacology | 2 | 14.0 |
Vasoconstrictor Agents/pharmacology | 2 | 5.0 |
Yohimbine/pharmacology | 5 | 55.0 |
Fluorescein-5-isothiocyanate/metabolism | 2 | 10.0 |
Myocardial Infarction/*blood/etiology | 3 | 37.0 |
Blood Preservation | 7 | 10.0 |
Cryopreservation | 3 | 2.0 |
von Willebrand Factor | 13 | 46.0 |
*Blood Preservation | 4 | 7.0 |
Photochemistry | 3 | 5.0 |
Plasma/*drug effects | 2 | 100.0 |
Safety | 5 | 3.0 |
Hemorrhage/drug therapy | 3 | 100.0 |
Hetastarch/*pharmacology | 2 | 40.0 |
Plasma Substitutes/*pharmacology | 2 | 25.0 |
Neoplasm Staging | 7 | 0.0 |
Cell Adhesion/drug effects/physiology | 3 | 5.0 |
Heparin/pharmacology | 8 | 3.0 |
Tumor Necrosis Factor-alpha/*metabolism | 3 | 0.0 |
Folic Acid/blood | 2 | 2.0 |
Diabetes Mellitus, Type 1/*physiopathology | 2 | 3.0 |
Regional Blood Flow/drug effects | 5 | 4.0 |
Endothelium/cytology/immunology | 2 | 25.0 |
*Graft Survival | 2 | 1.0 |
Hematopoietic Stem Cell Transplantation | 4 | 2.0 |
Acute-Phase Reaction | 2 | 4.0 |
Endothelium, Vascular/physiology | 9 | 13.0 |
*Flavonoids | 2 | 8.0 |
Peptide Fragments/blood | 7 | 6.0 |
Pulmonary Artery/physiopathology | 2 | 18.0 |
Lipids/*blood | 3 | 0.0 |
Lipoprotein(a)/blood | 4 | 6.0 |
Lipoproteins, LDL Cholesterol/blood | 7 | 1.0 |
Blood Platelets/cytology/*metabolism/physiology | 2 | 100.0 |
Histamine/pharmacology | 5 | 8.0 |
Receptors, Cell Surface/analysis | 2 | 2.0 |
Blood Coagulation/genetics | 3 | 37.0 |
Peptidyl-Dipeptidase A/*genetics | 2 | 0.0 |
Antithrombin III/metabolism | 21 | 17.0 |
Transplantation, Homologous | 9 | 1.0 |
Models, Animal | 3 | 1.0 |
Egtazic Acid/pharmacology | 4 | 3.0 |
Anticoagulants/*therapeutic use | 3 | 6.0 |
Dextrans/*therapeutic use | 2 | 66.0 |
Heparin, Low-Molecular-Weight/*therapeutic use | 2 | 10.0 |
Hypercholesterolemia/*blood | 3 | 14.0 |
Forearm/blood supply | 3 | 6.0 |
Infusions, Intra-Arterial | 2 | 3.0 |
Stimulation, Chemical | 5 | 1.0 |
Tissue Plasminogen Activator/*metabolism | 4 | 21.0 |
Longitudinal Studies | 8 | 0.0 |
*Angioplasty, Transluminal, Percutaneous Coronary | 4 | 8.0 |
Coronary Vessels/metabolism | 2 | 9.0 |
Endothelium, Vascular/metabolism | 21 | 8.0 |
Stents | 4 | 11.0 |
Peptides/chemical synthesis/chemistry/pharmacology | 2 | 33.0 |
Biological Transport | 9 | 0.0 |
Cytoplasmic Granules/metabolism | 7 | 18.0 |
Microscopy, Confocal | 6 | 0.0 |
*Electrocardiography | 2 | 3.0 |
Questionnaires | 7 | 1.0 |
Cell Culture Techniques/*methods | 3 | 3.0 |
Epoprostenol/secretion | 2 | 40.0 |
Fibrinolytic Agents/metabolism | 2 | 16.0 |
Thymidine/metabolism | 3 | 0.0 |
Tritium/diagnostic use | 2 | 1.0 |
Angioplasty, Transluminal, Percutaneous Coronary | 3 | 6.0 |
Myocardial Reperfusion | 2 | 11.0 |
Recombinant Proteins/genetics/metabolism | 9 | 1.0 |
Blood Component Transfusion | 3 | 18.0 |
Genes, Recessive | 8 | 1.0 |
Nuclear Family | 4 | 1.0 |
Plasma/*metabolism | 2 | 16.0 |
*Collagen | 4 | 11.0 |
*Platelet Adhesiveness | 31 | 68.0 |
*von Willebrand Factor | 6 | 75.0 |
Blood Platelets/*ultrastructure | 3 | 37.0 |
Calcium/*pharmacology | 2 | 2.0 |
ABO Blood-Group System/*genetics | 3 | 6.0 |
Linkage Disequilibrium | 4 | 0.0 |
Lod Score | 2 | 0.0 |
*Partial Thromboplastin Time | 2 | 11.0 |
Hypertension/blood/*physiopathology | 2 | 10.0 |
Coronary Thrombosis/*blood | 2 | 66.0 |
Postoperative Complications/*blood | 2 | 9.0 |
DNA Primers/chemistry | 6 | 0.0 |
Tumor Necrosis Factor-alpha/metabolism | 6 | 0.0 |
Platelet Function Tests/*instrumentation | 3 | 75.0 |
*Platelet Activation/drug effects | 2 | 14.0 |
Neovascularization, Pathologic | 4 | 1.0 |
Cell Division/physiology | 2 | 0.0 |
Diabetes Mellitus, Type 2/*blood | 4 | 3.0 |
Diabetic Nephropathies/*blood | 4 | 20.0 |
Diabetic Retinopathy/blood | 2 | 10.0 |
von Willebrand Factor/analysis/*metabolism | 9 | 81.0 |
Antioxidants/*administration & dosage | 3 | 18.0 |
Fatty Acids/blood | 2 | 4.0 |
Placebos | 7 | 2.0 |
Menopause | 2 | 0.0 |
*Social Class | 2 | 11.0 |
DNA, Complementary | 6 | 0.0 |
Gene Expression/physiology | 2 | 0.0 |
Protein Kinase C/metabolism | 2 | 0.0 |
RNA, Messenger/analysis | 8 | 0.0 |
Weibel-Palade Bodies/*metabolism | 2 | 50.0 |
Endothelial Growth Factors/*blood | 4 | 1.0 |
Lymphokines/*blood | 3 | 1.0 |
Recombinant Proteins/pharmacology | 13 | 0.0 |
Thrombin/metabolism/*pharmacology | 2 | 50.0 |
Immunosorbent Techniques | 10 | 3.0 |
Proteins/*metabolism | 4 | 0.0 |
*Tyrosine 3-Monooxygenase | 3 | 6.0 |
*Neoplasm Proteins | 3 | 0.0 |
Fibrinogen | 3 | 25.0 |
Thrombin/biosynthesis | 3 | 7.0 |
Desmopressin/*pharmacology | 23 | 67.0 |
Endothelium, Vascular/*drug effects/secretion | 5 | 83.0 |
Antithrombins/metabolism | 3 | 18.0 |
Behcet Syndrome/*blood | 2 | 40.0 |
Protein C/metabolism | 10 | 11.0 |
Protein S/metabolism | 4 | 11.0 |
Plasma Exchange/*methods | 3 | 75.0 |
Plasmapheresis/*methods | 2 | 25.0 |
Purpura, Thrombotic Thrombocytopenic/*therapy | 2 | 100.0 |
Hemagglutinins/metabolism | 3 | 37.0 |
Mass Screening | 2 | 1.0 |
Medical Records | 3 | 4.0 |
Platelet Function Tests/instrumentation | 2 | 66.0 |
ROC Curve | 3 | 1.0 |
Arteriosclerosis/etiology | 2 | 2.0 |
Hypertension/blood/complications/*physiopathology | 2 | 50.0 |
Epoprostenol/biosynthesis | 3 | 30.0 |
Genetic Markers | 2 | 0.0 |
Interleukin-1/metabolism | 4 | 1.0 |
Peptidyl-Dipeptidase A/metabolism | 3 | 6.0 |
Tissue Plasminogen Activator/biosynthesis | 2 | 13.0 |
Circadian Rhythm | 2 | 0.0 |
Alanine/chemistry | 3 | 4.0 |
Alkylation | 5 | 7.0 |
Computer Simulation | 4 | 1.0 |
Cytokines/*physiology | 2 | 1.0 |
Endothelin-1 | 2 | 18.0 |
Endothelins/blood | 2 | 14.0 |
*Heart Transplantation | 3 | 3.0 |
Interleukin-1/blood | 3 | 1.0 |
Microcirculation/drug effects | 2 | 7.0 |
*Vasodilation/drug effects | 2 | 40.0 |
Antigens/blood | 27 | 52.0 |
Endothelium, Vascular/drug effects/metabolism | 3 | 5.0 |
Vasodilation/drug effects | 4 | 7.0 |
von Willebrand Factor/chemistry/immunology/*metabolism | 4 | 100.0 |
von Willebrand Disease/blood/*genetics | 17 | 89.0 |
von Willebrand Factor/chemistry/*genetics | 3 | 100.0 |
Antibodies, Monoclonal/*therapeutic use | 2 | 0.0 |
Platelet Aggregation Inhibitors | 3 | 75.0 |
Thrombosis/*prevention & control | 2 | 11.0 |
*Adaptor Proteins, Vesicular Transport | 2 | 0.0 |
Antibodies, Monoclonal/immunology/pharmacology | 5 | 5.0 |
*Membrane Glycoproteins | 4 | 0.0 |
Platelet Activation/drug effects/*physiology | 4 | 23.0 |
Receptors, IgG/*metabolism | 2 | 3.0 |
src-Family Kinases/*metabolism | 2 | 1.0 |
Anthropometry | 3 | 1.0 |
DNA Primers | 13 | 0.0 |
Factor VIII/*genetics | 4 | 10.0 |
Lectins | 4 | 4.0 |
*Plant Lectins | 5 | 4.0 |
Viper Venoms/*pharmacology | 3 | 100.0 |
Anemia, Sickle Cell/*blood | 4 | 12.0 |
Recombinant Proteins/chemistry/genetics/metabolism | 2 | 0.0 |
Evaluation Studies | 13 | 1.0 |
Megakaryocytes/*metabolism | 2 | 6.0 |
Diabetic Angiopathies/blood | 3 | 21.0 |
von Willebrand Factor/*analysis/*genetics | 3 | 100.0 |
Administration, Cutaneous | 4 | 4.0 |
Estradiol/*pharmacology/therapeutic use | 2 | 33.0 |
Factor V/metabolism | 5 | 26.0 |
Hysterectomy | 3 | 3.0 |
Postmenopause/*blood | 2 | 4.0 |
von Willebrand Factor/immunology | 20 | 80.0 |
beta-Thromboglobulin/metabolism | 8 | 14.0 |
Edetic Acid/pharmacology | 9 | 5.0 |
Oligopeptides/pharmacology | 6 | 3.0 |
Protein Transport/drug effects | 2 | 3.0 |
Protein-Tyrosine Kinase/*metabolism | 4 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 9 | 0.0 |
Receptors, Cell Surface/antagonists & inhibitors/metabolism | 2 | 40.0 |
Thrombosis/chemically induced | 2 | 25.0 |
Binding Sites, Antibody | 4 | 1.0 |
Iodine Radioisotopes/diagnostic use | 8 | 2.0 |
von Willebrand Disease/*immunology | 2 | 100.0 |
Antibodies/immunology | 5 | 1.0 |
Blood Platelets/enzymology/*metabolism | 3 | 75.0 |
von Willebrand Factor/immunology/metabolism | 4 | 100.0 |
Blood Platelets/drug effects | 5 | 19.0 |
Factor VII/metabolism | 5 | 12.0 |
Hemoglobins/metabolism | 2 | 1.0 |
Peptide Hydrolases/metabolism | 10 | 6.0 |
Forearm/*blood supply | 3 | 14.0 |
Cell Differentiation/drug effects | 3 | 0.0 |
Growth Substances/*pharmacology | 2 | 0.0 |
*Hematopoiesis | 3 | 1.0 |
Megakaryocytes/*pathology | 2 | 6.0 |
Capillaries/metabolism | 2 | 8.0 |
Macrophages/*immunology | 2 | 0.0 |
Tumor Markers, Biological/*analysis | 5 | 0.0 |
Biological Transport/drug effects/physiology | 2 | 6.0 |
Cell Size/physiology | 2 | 5.0 |
Cytochalasin B/pharmacology | 3 | 3.0 |
Cytochalasin D/pharmacology | 3 | 3.0 |
Forskolin/pharmacology | 4 | 1.0 |
Nucleic Acid Synthesis Inhibitors/pharmacology | 2 | 1.0 |
Culture Media | 4 | 0.0 |
Endopeptidases/metabolism | 7 | 4.0 |
Fibrinogen/pharmacology | 4 | 26.0 |
Heat | 7 | 1.0 |
Luminescent Measurements | 3 | 3.0 |
Factor VIII/genetics/*metabolism | 8 | 100.0 |
von Willebrand Factor/genetics/*secretion | 2 | 100.0 |
*Blood Transfusion | 8 | 7.0 |
Aorta | 2 | 1.0 |
Endothelium, Vascular/metabolism/*physiology | 2 | 25.0 |
Factor VIII/pharmacology | 2 | 66.0 |
Receptors, Cell Surface/*metabolism | 26 | 4.0 |
Tumor Markers, Biological/metabolism | 3 | 0.0 |
Protein C/*metabolism | 4 | 2.0 |
Antifibrinolytic Agents/blood | 2 | 13.0 |
Blood Coagulation Factors | 3 | 33.0 |
Ischemia/blood | 2 | 66.0 |
Tissue Plasminogen Activator/immunology | 2 | 40.0 |
Urban Population | 2 | 1.0 |
*Endocytosis | 3 | 1.0 |
Receptors, Immunologic/*physiology | 2 | 1.0 |
von Willebrand Disease/*metabolism | 5 | 100.0 |
*Biological Assay | 3 | 14.0 |
Collagen/*analysis/metabolism | 2 | 100.0 |
Enzyme-Linked Immunosorbent Assay/*methods | 7 | 5.0 |
von Willebrand Factor/*analysis/immunology/metabolism | 2 | 100.0 |
Hemophilia A/blood/*genetics | 3 | 50.0 |
*ABO Blood-Group System | 4 | 10.0 |
C-Reactive Protein/*metabolism | 3 | 0.0 |
Menstrual Cycle/*metabolism | 2 | 6.0 |
Nitric-Oxide Synthase/*metabolism | 3 | 3.0 |
Blood Coagulation Factor Inhibitors/*blood | 2 | 50.0 |
Desmopressin/*therapeutic use | 22 | 70.0 |
*Premedication | 2 | 16.0 |
Arthritis, Rheumatoid/*blood/complications | 2 | 18.0 |
*Pregnancy Outcome | 2 | 3.0 |
Albuminuria/*physiopathology | 2 | 33.0 |
Diabetes Mellitus, Type 2/*physiopathology | 2 | 6.0 |
Diabetic Angiopathies/*physiopathology | 2 | 16.0 |
Endothelium, Vascular/*physiopathology/ultrasonography | 2 | 100.0 |
Glucose Clamp Technique | 2 | 1.0 |
*Blood Coagulation/drug effects | 3 | 37.0 |
Microscopy, Video | 2 | 2.0 |
*Stress, Mechanical | 6 | 40.0 |
Blood Glucose | 3 | 3.0 |
Fasting | 2 | 0.0 |
Fibrinolysis | 27 | 17.0 |
Hyperglycemia/*physiopathology | 2 | 25.0 |
Insulin Resistance | 4 | 2.0 |
Obesity | 2 | 3.0 |
Aspirin/*administration & dosage | 3 | 13.0 |
Hemostatics | 2 | 50.0 |
Platelet Count/drug effects | 4 | 11.0 |
RNA, Messenger/analysis/biosynthesis | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 11 | 0.0 |
Aspirin/administration & dosage | 3 | 42.0 |
Venous Thrombosis/metabolism | 2 | 66.0 |
Antibodies | 10 | 2.0 |
Methionine | 2 | 5.0 |
*Variation (Genetics) | 6 | 0.0 |
Calcium/pharmacology | 4 | 1.0 |
Manganese/pharmacology | 2 | 8.0 |
Peptide Fragments/metabolism/*pharmacology | 2 | 11.0 |
Protein Structure, Quaternary | 3 | 1.0 |
DNA/chemistry/genetics | 2 | 0.0 |
Evolution, Molecular | 2 | 0.0 |
Introns/*genetics | 2 | 1.0 |
*Phylogeny | 2 | 1.0 |
Blood Proteins/*physiology | 2 | 8.0 |
Fibronectins/physiology | 2 | 5.0 |
Glass | 8 | 28.0 |
Immunoglobulin G/physiology | 2 | 10.0 |
Polyethylene Glycols | 3 | 3.0 |
Polyurethanes | 2 | 33.0 |
Factor VIIa/*metabolism | 2 | 5.0 |
Arteriosclerosis/*pathology | 2 | 7.0 |
Lipoproteins/metabolism | 2 | 1.0 |
Haplotypes/genetics | 3 | 0.0 |
Antibodies, Monoclonal/*immunology | 15 | 2.0 |
Purpura, Thrombotic Thrombocytopenic/*diagnosis | 2 | 100.0 |
Antigens | 5 | 5.0 |
*Lung Transplantation | 3 | 11.0 |
Treatment Failure | 3 | 1.0 |
Bernard-Soulier Syndrome/*blood/genetics | 2 | 100.0 |
Platelet Adhesiveness/drug effects/*genetics | 3 | 100.0 |
Platelet Glycoprotein GPIb-IX Complex/*genetics | 2 | 50.0 |
England/epidemiology | 3 | 5.0 |
Forced Expiratory Volume | 2 | 2.0 |
*Blood Platelets/physiology | 2 | 100.0 |
Peptide Fragments/chemistry/genetics/metabolism | 2 | 2.0 |
Monocytes/drug effects | 2 | 3.0 |
Nitric Oxide | 2 | 20.0 |
Nitric-Oxide Synthase/*antagonists & inhibitors | 2 | 50.0 |
Thromboembolism/*blood | 3 | 37.0 |
DNA/genetics | 24 | 1.0 |
Georgia (Republic) | 2 | 28.0 |
Receptors, Adrenergic/*genetics | 2 | 33.0 |
Russia | 3 | 3.0 |
Uzbekistan | 2 | 100.0 |
*X Chromosome | 4 | 0.0 |
Cerebellar Neoplasms/*blood supply | 2 | 100.0 |
Medulloblastoma/*blood supply | 2 | 100.0 |
Neuroectodermal Tumors, Primitive, Peripheral/*blood supply | 2 | 100.0 |
Supratentorial Neoplasms/*blood supply | 2 | 100.0 |
Tumor Markers, Biological | 3 | 0.0 |
*Gene Expression Regulation | 2 | 0.0 |
Gene Transfer Techniques | 2 | 0.0 |
*Promoter Regions (Genetics) | 3 | 0.0 |
Apolipoprotein A-I/blood | 2 | 1.0 |
Apolipoproteins B/blood | 2 | 0.0 |
Dietary Fats, Unsaturated/*administration & dosage | 3 | 15.0 |
Diabetes Mellitus, Type 2/blood/*physiopathology | 2 | 10.0 |
Factor VIII/*immunology/metabolism | 3 | 42.0 |
Therapeutic Equivalency | 2 | 8.0 |
*Blood Pressure | 2 | 1.0 |
Weight Loss | 2 | 1.0 |
Bone Marrow Transplantation/*immunology | 2 | 1.0 |
Megakaryocytes/metabolism | 2 | 5.0 |
Veins | 4 | 7.0 |
Genetic Vectors/genetics | 2 | 0.0 |
Menstruation | 2 | 3.0 |
*Women's Health | 2 | 6.0 |
Epithelium/chemistry | 2 | 1.0 |
Hydrogen-Ion Concentration | 13 | 1.0 |
Tandem Repeat Sequences | 2 | 1.0 |
Threonine/analysis | 2 | 40.0 |
Cell Fractionation | 2 | 0.0 |
Centrifugation, Density Gradient | 2 | 0.0 |
Electrophoresis, Gel, Two-Dimensional | 3 | 0.0 |
Isoelectric Point | 2 | 1.0 |
Recombinant Proteins/metabolism/pharmacology | 2 | 1.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
*Coronary Angiography | 2 | 8.0 |
Factor Xa/antagonists & inhibitors | 3 | 6.0 |
Fatty Acids, Monounsaturated/*administration & dosage | 2 | 28.0 |
Diabetes Mellitus, Type 2/*complications | 2 | 5.0 |
Recombinant Proteins/chemistry/pharmacology | 2 | 8.0 |
Receptors, Fc/*metabolism | 2 | 5.0 |
Antineoplastic Combined Chemotherapy Protocols/*adverse effects | 2 | 4.0 |
Leukemia, Lymphocytic, Acute/*blood/*drug therapy | 2 | 100.0 |
Fibrinopeptide A/analysis | 3 | 7.0 |
Thromboplastin/analysis | 7 | 26.0 |
beta-Thromboglobulin/analysis | 6 | 7.0 |
*Alleles | 5 | 0.0 |
Brazil | 3 | 1.0 |
*Genetics, Population | 2 | 0.0 |
Solutions | 2 | 1.0 |
Antilipemic Agents/*pharmacology/therapeutic use | 2 | 40.0 |
Lipids/metabolism | 2 | 0.0 |
Biological Assay/*methods | 2 | 4.0 |
Epitopes/*immunology | 2 | 0.0 |
Hemophilia A/drug therapy/*immunology | 2 | 28.0 |
von Willebrand Factor/administration & dosage | 2 | 100.0 |
Nitric-Oxide Synthase/metabolism | 2 | 1.0 |
Tissue Plasminogen Activator/metabolism | 10 | 27.0 |
Calcium/*physiology | 6 | 5.0 |
Platelet Glycoprotein GPIb-IX Complex/*physiology | 6 | 85.0 |
Carrier Proteins/blood | 2 | 1.0 |
Platelet Membrane Glycoproteins/*analysis | 7 | 21.0 |
Tunica Intima/*ultrasonography | 2 | 25.0 |
Fibrinogen/*physiology | 4 | 66.0 |
Gene Amplification | 5 | 0.0 |
Italy | 3 | 0.0 |
von Willebrand Factor/genetics | 12 | 70.0 |
Endothelium, Vascular/*metabolism/physiopathology | 2 | 50.0 |
Endopeptidases/*pharmacology | 3 | 42.0 |
Recombinant Proteins/genetics | 2 | 1.0 |
Surgical Procedures, Operative/*adverse effects | 2 | 15.0 |
Thromboplastin/*analysis | 3 | 6.0 |
Cell Adhesion Molecules/biosynthesis | 2 | 2.0 |
Endothelium, Vascular/*cytology/*immunology/metabolism | 2 | 50.0 |
von Willebrand Factor/genetics/immunology/*metabolism | 2 | 100.0 |
Peptide Fragments/chemistry/metabolism | 3 | 2.0 |
Diabetes Mellitus, Type 1/*blood/physiopathology | 3 | 15.0 |
Purpura, Thrombotic Thrombocytopenic/*blood/physiopathology | 2 | 100.0 |
Sepsis/*blood/physiopathology | 2 | 66.0 |
Blood Platelets/*cytology/*physiology | 2 | 50.0 |
*Tissue Donors | 3 | 2.0 |
Endothelium, Vascular | 2 | 4.0 |
Surgical Flaps | 2 | 11.0 |
Echocardiography | 5 | 2.0 |
Immunoglobulins, Intravenous/*therapeutic use | 3 | 10.0 |
Extracellular Matrix | 2 | 8.0 |
Laminin | 2 | 2.0 |
Proteoglycans | 2 | 2.0 |
Blood Coagulation/immunology | 3 | 18.0 |
von Willebrand Disease/blood/*immunology | 6 | 100.0 |
Endothelium, Vascular/drug effects/physiology | 4 | 21.0 |
Tissue Plasminogen Activator/blood/drug effects | 2 | 100.0 |
Pregnancy Outcome | 3 | 1.0 |
Thrombophilia/blood/*complications | 2 | 33.0 |
Intercellular Adhesion Molecule-1/analysis | 4 | 3.0 |
Vascular Cell Adhesion Molecule-1/analysis | 9 | 23.0 |
Electrophoresis | 5 | 1.0 |
Transcription Factors/metabolism | 2 | 0.0 |
Recombinant Proteins | 9 | 1.0 |
E-Selectin/analysis | 4 | 20.0 |
Blood Viscosity/physiology | 2 | 66.0 |
Bone Marrow Transplantation/adverse effects | 2 | 13.0 |
Transplantation, Autologous | 6 | 1.0 |
Cross Reactions | 10 | 1.0 |
Transplantation, Heterologous/*immunology | 2 | 3.0 |
6-Ketoprostaglandin F1 alpha/blood | 2 | 11.0 |
Cyclosporine/*pharmacology | 4 | 3.0 |
Endothelium, Vascular/cytology/*drug effects | 2 | 2.0 |
Pre-Eclampsia/*blood | 5 | 10.0 |
Acute-Phase Proteins/analysis | 2 | 5.0 |
Endothelium, Vascular/*chemistry/*pathology | 2 | 50.0 |
Immunoassay | 4 | 1.0 |
Plasmin/analysis | 6 | 13.0 |
Arterioles/pathology | 2 | 28.0 |
von Willebrand Disease/*drug therapy | 17 | 100.0 |
von Willebrand Factor/*therapeutic use | 4 | 100.0 |
Tyrosine/*metabolism | 3 | 0.0 |
Protein C/analysis | 7 | 12.0 |
Protein S/analysis | 6 | 17.0 |
Administration, Intranasal | 6 | 7.0 |
Infusion Pumps | 2 | 7.0 |
Balloon Dilatation | 2 | 18.0 |
Heart Atria | 2 | 6.0 |
Platelet Activation/physiology | 8 | 28.0 |
Biomechanics | 4 | 3.0 |
Peptide Fragments/*pharmacology | 3 | 1.0 |
Platelet Aggregation/*immunology | 2 | 50.0 |
Models, Cardiovascular | 4 | 8.0 |
*Blood Donors | 6 | 5.0 |
Glycine/*genetics | 2 | 5.0 |
Purpura, Thrombotic Thrombocytopenic/*blood/genetics | 2 | 100.0 |
Smoking/*adverse effects | 3 | 1.0 |
Immunoglobulin G/immunology | 7 | 2.0 |
Isoantibodies/*immunology | 2 | 5.0 |
Isoantigens/*immunology | 2 | 2.0 |
Cold | 3 | 2.0 |
Organ Preservation | 2 | 9.0 |
Exercise | 2 | 1.0 |
Factor VII/analysis | 8 | 27.0 |
Life Style | 2 | 1.0 |
Blood Cell Count | 10 | 4.0 |
*Protein Conformation | 7 | 3.0 |
Hemolytic-Uremic Syndrome/*blood | 3 | 60.0 |
Hemophilia A/diagnosis | 2 | 100.0 |
von Willebrand Disease/diagnosis | 2 | 100.0 |
*Disease Models, Animal | 3 | 0.0 |
Factor VIII/administration & dosage/analysis/*therapeutic use | 2 | 100.0 |
Preoperative Care | 3 | 1.0 |
Platelet Membrane Glycoproteins | 20 | 43.0 |
Receptors, Cell Surface | 2 | 6.0 |
Thrombocytopenia/blood/*etiology | 2 | 40.0 |
Endotoxemia/*blood | 2 | 20.0 |
Neutrophils | 2 | 2.0 |
Heart Transplantation/*physiology | 2 | 9.0 |
Serum Albumin/analysis | 5 | 2.0 |
von Willebrand Factor/*chemistry/physiology | 2 | 100.0 |
France | 2 | 0.0 |
*Platelet Glycoprotein GPIb-IX Complex | 11 | 47.0 |
Electrophoresis/*methods | 3 | 12.0 |
von Willebrand Factor/*analysis/standards/therapeutic use | 2 | 100.0 |
Down-Regulation | 2 | 0.0 |
Plasma Volume/drug effects | 2 | 33.0 |
Lipids/*metabolism | 2 | 0.0 |
*Gene Frequency | 2 | 0.0 |
Microsatellite Repeats/*genetics | 2 | 0.0 |
Sampling Studies | 2 | 1.0 |
Immunoglobulins, Intravenous/therapeutic use | 4 | 10.0 |
Platelet Glycoprotein GPIIb-IIIa Complex/physiology | 5 | 50.0 |
Endopeptidases/physiology | 2 | 13.0 |
Fibrin/*physiology | 2 | 33.0 |
Phospholipids/blood | 4 | 3.0 |
Basement Membrane/metabolism | 2 | 3.0 |
Thrombasthenia/blood | 10 | 66.0 |
Plasminogen Inactivators/analysis | 7 | 50.0 |
Great Britain | 2 | 0.0 |
Hemophilia A/*diagnosis | 2 | 40.0 |
Laboratory Techniques and Procedures/*standards | 2 | 33.0 |
Prednisone/*therapeutic use | 4 | 14.0 |
Immunomagnetic Separation | 3 | 2.0 |
In Situ Hybridization | 2 | 0.0 |
Cell Adhesion/*physiology | 2 | 1.0 |
Platelet Membrane Glycoproteins/genetics/*physiology | 2 | 50.0 |
*Homozygote | 2 | 1.0 |
von Willebrand Disease/*etiology | 5 | 100.0 |
von Willebrand Factor/genetics/metabolism | 2 | 66.0 |
Body Weight | 3 | 0.0 |
Hemorrhage/*prevention & control | 4 | 66.0 |
von Willebrand Disease/*therapy | 7 | 87.0 |
Nucleic Acid Hybridization | 10 | 0.0 |
Ribonucleases | 2 | 4.0 |
Peptides/*pharmacology | 2 | 0.0 |
Tissue Plasminogen Activator/*secretion | 6 | 100.0 |
Amino Acid Substitution/genetics | 3 | 1.0 |
Asparagine/genetics | 2 | 5.0 |
Lipoproteins, LDL/*pharmacology | 2 | 3.0 |
Dehydroepiandrosterone Sulfate/blood | 2 | 2.0 |
Plasminogen Inactivators/*blood | 6 | 31.0 |
Sweden | 3 | 1.0 |
Hypertension/*blood/etiology | 2 | 50.0 |
Selectins/blood | 3 | 60.0 |
Biological Markers/*blood | 7 | 4.0 |
Confounding Factors (Epidemiology) | 2 | 3.0 |
Myocardial Infarction/blood/*etiology | 2 | 50.0 |
L Cells (Cell Line) | 3 | 1.0 |
Endothelium, Vascular/physiology/physiopathology | 2 | 66.0 |
Calcium/*metabolism | 8 | 1.0 |
*Signal Transduction | 3 | 0.0 |
Hypoglycemic Agents/*therapeutic use | 2 | 3.0 |
Tissue Polypeptide Antigen/blood | 2 | 50.0 |
Drug Contamination/*prevention & control | 2 | 66.0 |
Viruses/isolation & purification | 2 | 50.0 |
Factor VIII/*genetics/metabolism | 2 | 40.0 |
Cell Communication | 2 | 0.0 |
Neoplasm Transplantation | 4 | 0.0 |
Escherichia coli/genetics | 8 | 1.0 |
Clinical Trials | 3 | 0.0 |
Electrochemistry | 2 | 2.0 |
Immunoelectrophoresis, Two-Dimensional | 17 | 13.0 |
von Willebrand Factor/*isolation & purification/metabolism | 4 | 100.0 |
Cell Adhesion Molecules/*analysis | 6 | 5.0 |
Endothelium, Vascular/*chemistry | 4 | 20.0 |
Histocytochemistry | 3 | 0.0 |
Blood Proteins/*metabolism | 3 | 1.0 |
Blood Preservation/methods | 2 | 22.0 |
Endothelium, Vascular/cytology/metabolism | 8 | 6.0 |
*Liver Transplantation | 2 | 1.0 |
von Willebrand Factor/analysis/*physiology | 5 | 100.0 |
Fatty Acids, Omega-3/*administration & dosage | 2 | 15.0 |
Hyperlipidemia/drug therapy | 2 | 15.0 |
Protein Precursors/*blood | 2 | 2.0 |
*Cardiopulmonary Bypass | 4 | 4.0 |
Antibiotics, Peptide/*pharmacology | 2 | 40.0 |
Platelet Glycoprotein GPIIb-IIIa Complex/*physiology | 3 | 42.0 |
*Receptors, Cytokine | 2 | 1.0 |
Hydrolysis | 7 | 0.0 |
Protein S/*metabolism | 2 | 9.0 |
Mutation/*genetics | 2 | 0.0 |
Blood Platelets/*chemistry/drug effects/ultrastructure | 2 | 66.0 |
E-Selectin/metabolism | 2 | 4.0 |
Lipoproteins, LDL/metabolism | 3 | 1.0 |
Africa | 3 | 3.0 |
von Willebrand Factor/*analysis/physiology | 3 | 75.0 |
RNA Splicing | 2 | 0.0 |
Regulatory Sequences, Nucleic Acid | 4 | 0.0 |
*Transcription, Genetic | 2 | 0.0 |
von Willebrand Factor/biosynthesis/*genetics | 4 | 100.0 |
Blood Coagulation Tests/*methods | 2 | 12.0 |
Exons/genetics | 3 | 0.0 |
Factor VIII/analysis/*metabolism | 2 | 66.0 |
Hemophilia A/blood/genetics | 2 | 100.0 |
Thrombocytopenia/*blood/complications | 2 | 50.0 |
Biological Markers/blood/urine | 3 | 6.0 |
Diabetes Mellitus, Type 1/blood/*physiopathology/urine | 2 | 40.0 |
von Willebrand Disease/*blood/immunology | 2 | 100.0 |
*Protein Structure, Tertiary | 5 | 4.0 |
Antithrombins/*analysis | 2 | 22.0 |
Hypertension/epidemiology | 5 | 11.0 |
Smoking/epidemiology | 4 | 6.0 |
Immunoglobulin G/*immunology | 5 | 5.0 |
*Thiazolidinediones | 2 | 2.0 |
Albuminuria/*etiology/physiopathology | 2 | 66.0 |
Capillary Permeability | 4 | 4.0 |
Internal Mammary-Coronary Artery Anastomosis | 2 | 66.0 |
von Willebrand Factor/*urine | 2 | 100.0 |
Capillaries | 5 | 8.0 |
*Immunoenzyme Techniques | 2 | 1.0 |
Proportional Hazards Models | 3 | 0.0 |
Platelet Adhesiveness/*drug effects/physiology | 3 | 100.0 |
von Willebrand Factor/chemistry/*immunology | 3 | 100.0 |
Urinary Plasminogen Activator/blood | 4 | 30.0 |
*Forensic Medicine | 2 | 4.0 |
Binding, Competitive/immunology | 2 | 2.0 |
Endothelium, Vascular/*cytology | 12 | 7.0 |
Umbilical Cord | 2 | 15.0 |
Prenatal Diagnosis | 2 | 1.0 |
Pseudogenes | 3 | 1.0 |
Intercellular Adhesion Molecule-1/biosynthesis | 2 | 2.0 |
Antigens/immunology | 3 | 2.0 |
Chromatography, Agarose | 2 | 4.0 |
Magnesium/pharmacology | 2 | 1.0 |
Autoantibodies/*immunology | 5 | 2.0 |
Microcirculation/*pathology | 3 | 15.0 |
Exocytosis/drug effects/*physiology | 2 | 22.0 |
Intracellular Fluid/metabolism | 2 | 1.0 |
Secretory Rate/drug effects | 5 | 5.0 |
Blood Circulation/*physiology | 2 | 40.0 |
Adrenal Cortex Hormones/therapeutic use | 2 | 2.0 |
Splenectomy | 5 | 7.0 |
Sex Distribution | 2 | 0.0 |
8-Bromo Cyclic Adenosine Monophosphate/pharmacology | 2 | 2.0 |
Bucladesine/pharmacology | 3 | 1.0 |
Cholera Toxin/pharmacology | 2 | 2.0 |
Endothelium, Vascular/cytology/*drug effects/secretion | 2 | 100.0 |
Epoprostenol/pharmacology | 6 | 24.0 |
Diabetes Mellitus/epidemiology | 2 | 6.0 |
Fibrinolysis/*physiology | 10 | 13.0 |
Obesity/epidemiology | 2 | 8.0 |
Protein Precursors/genetics | 2 | 2.0 |
Cell Adhesion/physiology | 3 | 1.0 |
Extracellular Matrix/physiology | 4 | 4.0 |
Blood Platelets/metabolism/*ultrastructure | 2 | 40.0 |
Serum Albumin, Bovine/metabolism | 2 | 9.0 |
Arteriosclerosis/pathology | 2 | 15.0 |
Plasma/*chemistry | 5 | 38.0 |
Cell Adhesion Molecules/analysis | 5 | 3.0 |
Endothelium, Vascular/chemistry/*metabolism | 2 | 50.0 |
Graft Rejection/*metabolism | 2 | 25.0 |
HLA Antigens/analysis | 3 | 1.0 |
von Willebrand Disease/genetics/*metabolism | 2 | 100.0 |
von Willebrand Factor/*chemistry/genetics/metabolism | 3 | 100.0 |
Endothelium, Vascular/cytology/*secretion | 3 | 75.0 |
Exocytosis/*drug effects | 3 | 25.0 |
Thionucleotides/pharmacology | 2 | 3.0 |
Ristocetin/analysis | 5 | 100.0 |
Forecasting | 2 | 0.0 |
Leukocytes/physiology | 2 | 3.0 |
Chemistry, Physical | 4 | 2.0 |
Thromboxane B2/metabolism | 2 | 9.0 |
Crotalid Venoms/*pharmacology | 9 | 69.0 |
Hemophilia A/*blood/*genetics | 2 | 66.0 |
Aurintricarboxylic Acid/pharmacology | 3 | 33.0 |
Arteriosclerosis/*etiology | 4 | 10.0 |
von Willebrand Factor/genetics/metabolism/*physiology | 2 | 100.0 |
Complement Activation | 3 | 1.0 |
Isoenzymes | 2 | 1.0 |
*Mutagenesis, Site-Directed | 3 | 3.0 |
von Willebrand Factor/*antagonists & inhibitors | 5 | 100.0 |
Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Thymidine Phosphorylase/*metabolism | 2 | 8.0 |
1-Methyl-3-isobutylxanthine/pharmacology | 2 | 2.0 |
Second Messenger Systems/*physiology | 2 | 7.0 |
Hela Cells | 2 | 0.0 |
von Willebrand Factor/*genetics/metabolism | 15 | 100.0 |
Platelet Aggregation Inhibitors/pharmacology/*therapeutic use | 2 | 40.0 |
Desmopressin/*administration & dosage | 9 | 75.0 |
Blood Platelets/drug effects/metabolism/*pathology | 2 | 66.0 |
Freezing | 5 | 5.0 |
Continental Population Groups | 4 | 2.0 |
Myocardial Ischemia/complications | 2 | 40.0 |
Blood Platelets/*enzymology | 2 | 2.0 |
Proto-Oncogene Protein pp60(c-src)/metabolism | 2 | 5.0 |
Epitopes/metabolism | 2 | 3.0 |
Peptides/metabolism | 3 | 1.0 |
Recombinant Proteins/biosynthesis/chemistry | 3 | 3.0 |
von Willebrand Factor/metabolism/pharmacology | 3 | 75.0 |
Laminin/metabolism | 3 | 2.0 |
Hypertension/*blood/complications | 2 | 20.0 |
von Willebrand Factor/genetics/*physiology | 3 | 100.0 |
Endothelins/metabolism | 2 | 25.0 |
Blood Platelets/metabolism/*physiology | 5 | 38.0 |
Umbilical Veins/metabolism | 2 | 6.0 |
*Helicobacter pylori | 2 | 1.0 |
Smoking/blood | 3 | 7.0 |
Cardiopulmonary Bypass/adverse effects | 2 | 25.0 |
Peptide Hydrolases/*blood | 2 | 18.0 |
Prothrombin | 2 | 4.0 |
Antigens/metabolism | 8 | 12.0 |
Glucose/metabolism | 3 | 1.0 |
Intercellular Adhesion Molecule-1/metabolism | 2 | 1.0 |
CD4 Lymphocyte Count | 2 | 0.0 |
Blood Vessels/pathology | 2 | 5.0 |
Sex Hormone-Binding Globulin/analysis | 2 | 0.0 |
Antiplasmin/metabolism | 2 | 7.0 |
Plasminogen/metabolism | 4 | 10.0 |
Thrombosis/*blood/*etiology | 2 | 50.0 |
Ionomycin/pharmacology | 2 | 0.0 |
Protein Kinase C/physiology | 2 | 1.0 |
Angina Pectoris/*blood | 4 | 19.0 |
Angina, Unstable/*blood | 4 | 28.0 |
Medical History Taking | 2 | 5.0 |
Postoperative Complications/*prevention & control | 2 | 11.0 |
Antiplasmin/analysis | 4 | 10.0 |
Antigens, CD45/analysis | 2 | 0.0 |
Lung/enzymology | 2 | 3.0 |
*Saccharomyces cerevisiae Proteins | 2 | 0.0 |
Models, Structural | 4 | 2.0 |
*Protein Structure, Secondary | 3 | 2.0 |
Oligopeptides | 2 | 6.0 |
Isoleucine/genetics | 2 | 7.0 |
Restriction Mapping | 11 | 0.0 |
Autoantibodies/immunology | 2 | 1.0 |
Lupus Erythematosus, Systemic/*complications | 3 | 17.0 |
Vasculitis/*etiology | 2 | 20.0 |
Tumor Markers, Biological/analysis | 2 | 0.0 |
Prednisolone/therapeutic use | 5 | 5.0 |
Coronary Vessels/pathology | 3 | 6.0 |
Injections, Subcutaneous | 8 | 2.0 |
Blotting, Northern | 7 | 0.0 |
Endothelium, Vascular/drug effects/*metabolism | 5 | 6.0 |
Radioimmunoassay | 10 | 0.0 |
Binding Sites/drug effects | 2 | 3.0 |
Scattering, Radiation | 3 | 2.0 |
von Willebrand Factor/biosynthesis/*metabolism | 2 | 100.0 |
Renin/blood | 2 | 0.0 |
Ristocetin/*analysis | 2 | 100.0 |
Ultracentrifugation | 4 | 2.0 |
von Willebrand Factor/*isolation & purification | 8 | 100.0 |
Blood Vessels/*physiology | 4 | 33.0 |
Immunoglobulin G | 3 | 2.0 |
Platelet Membrane Glycoproteins/*genetics | 6 | 20.0 |
Promoter Regions (Genetics)/genetics | 2 | 0.0 |
*Methionine | 2 | 33.0 |
Recombinant Proteins/biosynthesis | 4 | 0.0 |
*Valine | 2 | 18.0 |
Thrombomodulin/*analysis | 8 | 57.0 |
Obesity/*blood | 3 | 3.0 |
von Willebrand Disease/blood/*drug therapy | 13 | 100.0 |
Extracellular Matrix/*metabolism/ultrastructure | 2 | 40.0 |
Particle Size | 3 | 1.0 |
Hemophilia A/*genetics | 4 | 19.0 |
*Heterozygote | 2 | 0.0 |
Coronary Disease/*physiopathology | 2 | 11.0 |
Endothelium, Vascular/cytology/drug effects/*metabolism | 4 | 4.0 |
Epinephrine/*pharmacology | 6 | 22.0 |
Albuminuria/metabolism | 2 | 20.0 |
*Antibodies, Monoclonal | 9 | 3.0 |
Reagent Kits, Diagnostic | 2 | 1.0 |
Blood Platelets/drug effects/physiology | 4 | 50.0 |
*Platelet Adhesiveness/drug effects | 6 | 66.0 |
RNA, Messenger/metabolism | 6 | 0.0 |
Oxidation-Reduction | 6 | 0.0 |
von Willebrand Disease/blood/*genetics/physiopathology | 2 | 100.0 |
Protease Inhibitors/pharmacology | 2 | 0.0 |
Platelet Aggregation/drug effects/*physiology | 6 | 35.0 |
Repetitive Sequences, Nucleic Acid | 8 | 0.0 |
Tissue Donors | 3 | 1.0 |
Thrombomodulin/*metabolism | 2 | 8.0 |
Japan/epidemiology | 3 | 0.0 |
Membrane Glycoproteins/*metabolism | 4 | 0.0 |
Thrombospondins | 14 | 13.0 |
Physical Endurance/*physiology | 3 | 6.0 |
Quality Control | 5 | 2.0 |
Kidney Failure, Chronic/blood/therapy | 3 | 9.0 |
Cell Line, Tumor | 3 | 0.0 |
Procollagen/blood | 3 | 10.0 |
Thrombin/analysis | 2 | 11.0 |
Arginine/genetics | 3 | 1.0 |
Cations, Divalent | 2 | 2.0 |
Densitometry | 4 | 2.0 |
Glutamine/genetics | 2 | 4.0 |
Antigens, Human Platelet/analysis | 2 | 40.0 |
von Willebrand Disease/blood/*etiology | 6 | 100.0 |
Factor VIII/antagonists & inhibitors | 2 | 50.0 |
Goats | 2 | 2.0 |
von Willebrand Disease/*physiopathology | 2 | 100.0 |
Adenosine Diphosphate/*pharmacology | 6 | 31.0 |
Bias (Epidemiology) | 2 | 3.0 |
Blood Platelets/*drug effects/physiology | 3 | 27.0 |
Intercellular Adhesion Molecule-1/*biosynthesis | 2 | 4.0 |
von Willebrand Factor/*biosynthesis/genetics | 3 | 75.0 |
*Genes, Recessive | 3 | 2.0 |
Israel | 2 | 1.0 |
Chromosomes, Human, Pair 12 | 6 | 3.0 |
Arteries | 3 | 5.0 |
Renal Agents/*administration & dosage | 2 | 66.0 |
Erythrocyte Aggregation | 2 | 15.0 |
*Fetal Blood | 3 | 6.0 |
Plasminogen Inactivators/blood | 10 | 38.0 |
Fluorescent Antibody Technique, Direct | 2 | 1.0 |
von Willebrand Factor/analysis/*biosynthesis | 3 | 100.0 |
Molecular Structure | 9 | 1.0 |
Sulfates/metabolism | 2 | 3.0 |
Cysteine/genetics | 2 | 1.0 |
Detergents/pharmacology | 5 | 4.0 |
Solvents/pharmacology | 5 | 20.0 |
Receptor, PAR-2 | 2 | 18.0 |
von Willebrand Factor/*analysis/immunology | 12 | 100.0 |
Dogs/*blood | 3 | 50.0 |
Enzyme-Linked Immunosorbent Assay/veterinary | 2 | 14.0 |
Proteinuria/blood | 2 | 25.0 |
Polymyalgia Rheumatica/blood | 3 | 75.0 |
Adenosine Triphosphate/pharmacology | 2 | 2.0 |
Epithelial Cells | 4 | 0.0 |
Intracellular Membranes/metabolism | 2 | 1.0 |
von Willebrand Factor/*biosynthesis/secretion | 2 | 100.0 |
Blood Platelets/*physiology/ultrastructure | 3 | 37.0 |
Purpura, Thrombotic Thrombocytopenic/*blood/pathology | 2 | 66.0 |
Calcium/physiology | 3 | 1.0 |
Down-Regulation/drug effects | 2 | 0.0 |
Phorbol Esters/pharmacology | 2 | 1.0 |
Intercellular Adhesion Molecule-1/*analysis | 2 | 10.0 |
Neovascularization, Pathologic/*physiopathology | 2 | 2.0 |
Microscopy, Atomic Force | 2 | 9.0 |
Epitopes/chemistry/genetics | 2 | 9.0 |
Culture Media, Conditioned | 2 | 0.0 |
von Willebrand Disease/*diagnosis/genetics | 5 | 100.0 |
Endothelium/cytology/drug effects | 2 | 18.0 |
Fibrinolysis/drug effects | 5 | 13.0 |
Methionine/*genetics | 2 | 13.0 |
Endoplasmic Reticulum/metabolism | 4 | 1.0 |
Fibronectins/analysis | 6 | 11.0 |
Urinary Plasminogen Activator/analysis | 2 | 12.0 |
Cardiopulmonary Bypass/*adverse effects | 6 | 22.0 |
Inflammation Mediators/blood | 2 | 4.0 |
Myeloproliferative Disorders/*complications | 2 | 66.0 |
Serotonin/*blood | 2 | 14.0 |
von Willebrand Factor/*pharmacokinetics | 2 | 100.0 |
Cell Survival/drug effects | 3 | 0.0 |
Thymidine Kinase/genetics | 2 | 2.0 |
Cell Separation/*methods | 2 | 1.0 |
Cytoplasmic Granules/chemistry | 3 | 15.0 |
Detergents | 3 | 2.0 |
Octoxynol | 2 | 3.0 |
Pregnancy Complications, Hematologic/*blood | 3 | 18.0 |
von Willebrand Factor/chemistry/*pharmacology | 2 | 100.0 |
Diabetic Retinopathy/*blood/etiology | 2 | 66.0 |
von Willebrand Disease/*chemically induced | 3 | 100.0 |
Fibroblast Growth Factors/analysis | 2 | 40.0 |
Genes/*genetics | 2 | 4.0 |
Pseudogenes/*genetics | 2 | 2.0 |
Staphylococcal Protein A | 2 | 13.0 |
von Willebrand Factor/drug effects/*secretion | 2 | 100.0 |
Cell Adhesion Molecules/*metabolism | 6 | 2.0 |
Extracellular Matrix Proteins/*metabolism | 2 | 3.0 |
Blood Coagulation Disorders/*etiology | 5 | 25.0 |
Plasmin/metabolism | 8 | 9.0 |
Protein Conformation/drug effects | 2 | 3.0 |
Sodium Chloride/pharmacology | 2 | 2.0 |
Blood Platelets/ultrastructure | 4 | 44.0 |
Cytosol/*metabolism | 2 | 6.0 |
Drug Therapy, Combination | 6 | 0.0 |
Platelet Aggregation Inhibitors/*administration & dosage | 2 | 40.0 |
Cations, Divalent/pharmacology | 2 | 5.0 |
Receptors, Cell Surface/physiology | 5 | 4.0 |
Creatine Kinase/pharmacology | 2 | 50.0 |
Exercise/physiology | 2 | 3.0 |
Phosphocreatine/pharmacology | 2 | 50.0 |
*Magnetic Resonance Imaging | 2 | 1.0 |
Hemorrhage/*etiology | 4 | 44.0 |
*von Willebrand Disease | 2 | 100.0 |
Buffers | 3 | 2.0 |
Diabetes Mellitus, Type 1/*blood/physiopathology/urine | 2 | 40.0 |
N-Acetylneuraminic Acid | 2 | 5.0 |
Sialic Acids/*blood | 2 | 20.0 |
Microchemistry | 2 | 6.0 |
Obesity/*blood/physiopathology | 2 | 16.0 |
Thrombin/*metabolism | 10 | 12.0 |
DNA Primers/genetics | 4 | 0.0 |
von Willebrand Disease/classification/*genetics/metabolism | 2 | 100.0 |
Endothelium, Vascular/drug effects/*physiology | 4 | 7.0 |
Spectrometry, Fluorescence | 4 | 0.0 |
*Heat | 2 | 1.0 |
Precipitation | 7 | 4.0 |
Endothelium, Vascular/*immunology | 5 | 5.0 |
Calcium/*blood | 4 | 4.0 |
Cell Membrane/*metabolism | 3 | 1.0 |
Indomethacin/pharmacology | 3 | 1.0 |
von Willebrand Factor/*metabolism/pharmacology | 6 | 100.0 |
Clone Cells | 2 | 0.0 |
HLA-D Antigens/analysis | 2 | 3.0 |
Plasminogen/analysis | 4 | 23.0 |
von Willebrand Factor/biosynthesis/*genetics/metabolism | 2 | 100.0 |
Blotting, Southern | 4 | 0.0 |
Peptide Fragments/chemistry/pharmacology | 2 | 7.0 |
Laminin/biosynthesis | 2 | 15.0 |
Vascular Cell Adhesion Molecule-1/biosynthesis | 2 | 5.0 |
Antigens, CD31 | 6 | 16.0 |
Antigens, CD36/metabolism | 2 | 4.0 |
Fluorescent Dyes | 3 | 0.0 |
Interferon-gamma, Recombinant/pharmacology | 2 | 1.0 |
Antibodies/*analysis | 2 | 1.0 |
Endothelium, Vascular/*immunology/pathology | 2 | 28.0 |
Blood Platelets/metabolism/ultrastructure | 3 | 75.0 |
Fibrinopeptide A/metabolism | 4 | 16.0 |
Hemorrhagic Disorders/*blood | 2 | 100.0 |
Ristocetin/blood | 4 | 66.0 |
Uremia/*blood/therapy | 4 | 23.0 |
Bernard-Soulier Syndrome/pathology | 2 | 100.0 |
Cytoplasmic Granules/*chemistry | 2 | 11.0 |
Megakaryocytes/ultrastructure | 2 | 100.0 |
Thrombocytopenia/etiology | 5 | 18.0 |
Discriminant Analysis | 2 | 2.0 |
Raynaud Disease/*blood | 3 | 42.0 |
Complement/*physiology | 2 | 2.0 |
Anoxia/*metabolism | 2 | 3.0 |
Neutrophils/*immunology | 2 | 1.0 |
Androstadienes/pharmacology | 2 | 0.0 |
Biological Transport/drug effects | 2 | 0.0 |
Blood Platelets/*drug effects/metabolism/ultrastructure | 2 | 40.0 |
Microfilaments/*physiology | 2 | 28.0 |
Myosin-Light-Chain Kinase/antagonists & inhibitors | 2 | 40.0 |
Blood Platelets/*secretion | 2 | 18.0 |
Monocytes/*physiology | 2 | 1.0 |
Furin | 4 | 8.0 |
Transforming Growth Factor beta/biosynthesis | 2 | 4.0 |
*Omentum | 2 | 20.0 |
Antibodies, Antineutrophil Cytoplasmic/*blood | 2 | 8.0 |
Isoantibodies/*blood | 3 | 15.0 |
Recombinant Proteins/therapeutic use | 5 | 1.0 |
United States/epidemiology | 2 | 0.0 |
Pregnancy/*blood | 2 | 1.0 |
Pregnancy Trimester, Third | 2 | 1.0 |
Mice, SCID | 4 | 0.0 |
*Cardiac Surgical Procedures | 2 | 4.0 |
*Hemostasis, Surgical | 2 | 50.0 |
Heparin/therapeutic use | 3 | 7.0 |
Factor VIII/*therapeutic use | 10 | 58.0 |
Purpura, Thrombotic Thrombocytopenic/*blood/therapy | 4 | 100.0 |
Escherichia coli | 2 | 0.0 |
Radioligand Assay | 5 | 1.0 |
Collagen/*blood | 4 | 18.0 |
Plasminogen Activators/blood | 2 | 28.0 |
*Repetitive Sequences, Nucleic Acid | 6 | 1.0 |
Thromboplastin/*metabolism | 2 | 1.0 |
Endothelium, Vascular/*metabolism/ultrastructure | 5 | 33.0 |
Hemostasis/*genetics | 2 | 50.0 |
von Willebrand Disease/genetics | 2 | 100.0 |
*Plasma | 3 | 23.0 |
Endothelium, Vascular/*secretion | 3 | 37.0 |
Exocytosis/physiology | 2 | 8.0 |
Bernard-Soulier Syndrome/blood | 5 | 71.0 |
Fibrin/*metabolism | 4 | 10.0 |
Cytokines/blood | 2 | 0.0 |
von Willebrand Factor/*biosynthesis/*chemistry/isolation & purification | 2 | 100.0 |
Cell Movement | 2 | 0.0 |
Stem Cells/*cytology | 2 | 2.0 |
Isoantibodies/metabolism | 2 | 50.0 |
Cryoultramicrotomy | 2 | 25.0 |
Plasmapheresis | 6 | 16.0 |
Fluorescein-5-isothiocyanate | 2 | 1.0 |
Hemodilution | 3 | 50.0 |
Postoperative Complications | 3 | 2.0 |
von Willebrand Factor/analysis/immunology | 5 | 55.0 |
Endothelium, Vascular/*cytology/physiology | 2 | 10.0 |
Haplorhini | 3 | 1.0 |
Promoter Regions (Genetics) | 3 | 0.0 |
Factor XI/metabolism | 2 | 40.0 |
Endothelium, Vascular/*cytology/drug effects/*metabolism | 2 | 33.0 |
P-Selectin | 8 | 15.0 |
Antifibrinolytic Agents/*analysis | 2 | 25.0 |
Anti-Inflammatory Agents/therapeutic use | 2 | 2.0 |
Salivary Proteins/*pharmacology | 2 | 50.0 |
Antigens, CD/blood | 2 | 0.0 |
Cisplatin/*adverse effects | 2 | 16.0 |
Platelet Membrane Glycoproteins/*antagonists & inhibitors | 5 | 62.0 |
Vasculitis/*blood | 3 | 50.0 |
Constriction | 4 | 19.0 |
Veins/*physiology | 3 | 75.0 |
Europe | 2 | 0.0 |
Thrombin Time | 2 | 9.0 |
Ristocetin/antagonists & inhibitors/pharmacology | 3 | 100.0 |
Cause of Death | 3 | 1.0 |
Plasminogen Activator Inhibitor 1/*analysis | 4 | 33.0 |
Factor VII/*metabolism | 2 | 9.0 |
Proteins/analysis | 2 | 1.0 |
Membrane Glycoproteins/metabolism | 2 | 0.0 |
von Willebrand Disease/blood/*classification/genetics | 2 | 100.0 |
Polymers/metabolism | 2 | 4.0 |
Melphalan/therapeutic use | 2 | 11.0 |
Desmopressin/adverse effects/*therapeutic use | 4 | 100.0 |
*Hip Prosthesis | 2 | 6.0 |
E-Selectin | 6 | 7.0 |
Vascular Cell Adhesion Molecule-1 | 4 | 4.0 |
Sequence Analysis | 2 | 0.0 |
*Chromosomes, Human, Pair 12 | 9 | 3.0 |
Phospholipids/*metabolism | 2 | 1.0 |
Adenosine Triphosphate/blood | 3 | 10.0 |
Crotalid Venoms/*chemistry | 3 | 75.0 |
Erythrocytes/metabolism | 2 | 1.0 |
*Trimeresurus | 2 | 66.0 |
Linkage (Genetics)/genetics | 2 | 0.0 |
Vascular Endothelial Growth Factor A/*biosynthesis | 2 | 3.0 |
Alanine/metabolism | 2 | 5.0 |
Epitopes/genetics | 2 | 2.0 |
von Willebrand Factor/chemistry/immunology | 2 | 100.0 |
Chelating Agents/pharmacology | 2 | 2.0 |
Egtazic Acid/analogs & derivatives/pharmacology | 2 | 7.0 |
Inflammation/physiopathology | 2 | 3.0 |
Signal Transduction/drug effects/physiology | 2 | 0.0 |
Factor VIII/immunology/*metabolism | 3 | 50.0 |
von Willebrand Factor/immunology/isolation & purification/*metabolism | 2 | 100.0 |
Asian Continental Ancestry Group | 2 | 0.0 |
Rats, Inbred Strains | 2 | 0.0 |
Antigens, Differentiation, Myelomonocytic/*analysis | 2 | 1.0 |
Cell Compartmentation | 3 | 0.0 |
Antifibrinolytic Agents/metabolism | 3 | 14.0 |
Chemistry | 7 | 3.0 |
Cytological Techniques | 2 | 5.0 |
Fixatives | 3 | 4.0 |
Platelet Membrane Glycoproteins/immunology/*metabolism | 8 | 66.0 |
von Willebrand Disease/blood/*chemically induced | 2 | 100.0 |
von Willebrand Factor/isolation & purification/*metabolism | 14 | 100.0 |
Brain/blood supply | 2 | 5.0 |
Phosphotyrosine | 2 | 0.0 |
Blood Platelets/chemistry | 4 | 13.0 |
Renal Dialysis/*adverse effects | 6 | 4.0 |
Uremia/*blood | 5 | 15.0 |
Antigens, CD/*analysis | 2 | 0.0 |
Blood Coagulation Factors/*biosynthesis | 3 | 75.0 |
Fingers/blood supply | 2 | 14.0 |
Antigen-Antibody Complex/analysis | 4 | 3.0 |
Blood Transfusion/*adverse effects | 2 | 3.0 |
Mathematics | 6 | 3.0 |
Polylysine/pharmacology | 3 | 15.0 |
Statistics | 9 | 1.0 |
Immunodiffusion | 3 | 1.0 |
Umbilical Veins/cytology/drug effects | 2 | 22.0 |
Creatine Kinase/blood | 3 | 2.0 |
Leukocytes/metabolism | 3 | 2.0 |
Cardiovascular Diseases/complications | 2 | 20.0 |
Blood Platelets/metabolism/*pathology | 2 | 33.0 |
Angioplasty, Balloon/*adverse effects | 2 | 28.0 |
Tooth Extraction | 2 | 33.0 |
von Willebrand Disease/blood/*drug therapy/genetics | 2 | 100.0 |
Diabetes Mellitus, Type 2/*blood/complications | 2 | 10.0 |
*Prothrombin Time | 2 | 10.0 |
Smoking/adverse effects/*blood | 2 | 40.0 |
Antigens, CD34/*immunology | 2 | 2.0 |
Cell Differentiation/*drug effects | 2 | 1.0 |
Tissue Engineering/methods | 2 | 16.0 |
Gene Library | 6 | 0.0 |
Platelet Membrane Glycoproteins/*antagonists & inhibitors/metabolism | 2 | 66.0 |
Ristocetin/antagonists & inhibitors | 3 | 100.0 |
Factor VIII/*isolation & purification | 6 | 100.0 |
Hemophilia A/*blood | 5 | 35.0 |
Oligopeptides/metabolism/*pharmacology | 2 | 33.0 |
Ultrafiltration | 2 | 3.0 |
Factor VIII/genetics/metabolism | 2 | 50.0 |
von Willebrand Disease/blood/*etiology/immunology | 2 | 100.0 |
Hematopoietic Stem Cells/*cytology | 2 | 0.0 |
*Linkage (Genetics) | 3 | 0.0 |
Estradiol/blood | 3 | 0.0 |
Glycoproteins/metabolism | 6 | 3.0 |
Receptors, Vitronectin | 6 | 35.0 |
Vitronectin | 6 | 16.0 |
Receptors, Cytoadhesin/*metabolism | 3 | 37.0 |
Antibodies, Monoclonal/therapeutic use | 2 | 1.0 |
*Aging | 2 | 1.0 |
Endothelial Cells/*cytology/metabolism | 2 | 40.0 |
Peptidyl-Dipeptidase A/blood | 2 | 2.0 |
Scleroderma, Systemic/*blood/complications/physiopathology | 2 | 100.0 |
Rats, Wistar | 4 | 0.0 |
*Aspartic Acid | 2 | 15.0 |
Fibrin/*analysis | 2 | 16.0 |
Endopeptidases | 2 | 5.0 |
Iodine Radioisotopes | 6 | 1.0 |
Thrombocythemia, Hemorrhagic/*blood | 2 | 20.0 |
Blood Platelets/*immunology | 4 | 5.0 |
Cytoplasm/*metabolism | 2 | 1.0 |
Platelet Membrane Glycoproteins/immunology | 3 | 16.0 |
DNA/blood/genetics/isolation & purification | 3 | 7.0 |
von Willebrand Disease/blood/classification/*genetics | 2 | 100.0 |
Formaldehyde | 2 | 2.0 |
von Willebrand Factor/*metabolism/physiology | 3 | 100.0 |
Bacterial Toxins/pharmacology | 2 | 4.0 |
Fibrinolysis/drug effects/*physiology | 2 | 66.0 |
*Phytotherapy | 4 | 4.0 |
Drug Evaluation | 5 | 2.0 |
Factor VIII/*administration & dosage | 3 | 50.0 |
Hemostasis, Surgical | 2 | 40.0 |
*Albuminuria | 2 | 6.0 |
Tetradecanoylphorbol Acetate/*pharmacology | 2 | 0.0 |
*Blood Coagulation Tests | 4 | 17.0 |
Factor XIII/metabolism | 2 | 28.0 |
Actins/metabolism | 4 | 0.0 |
Neutrophils/*enzymology | 2 | 1.0 |
Golgi Apparatus/metabolism | 3 | 1.0 |
Integrins/chemistry/*metabolism | 2 | 33.0 |
Interleukin-1/pharmacology | 2 | 0.0 |
Rats, Inbred SHR | 2 | 2.0 |
Rats, Inbred WKY | 2 | 2.0 |
Fibrinopeptide A/*metabolism | 2 | 28.0 |
von Willebrand Factor/genetics/*immunology | 3 | 100.0 |
Antigens, CD36 | 2 | 1.0 |
Intercellular Adhesion Molecule-1 | 4 | 1.0 |
Hemorrhage/genetics | 3 | 75.0 |
Blood Group Antigens | 3 | 7.0 |
Epitopes/*analysis | 5 | 3.0 |
Antibodies, Monoclonal/diagnostic use | 18 | 2.0 |
Epitopes/analysis | 6 | 2.0 |
Immunoglobulins, Fab | 5 | 9.0 |
Peptides/chemical synthesis/pharmacology | 2 | 25.0 |
Phospholipids/metabolism | 2 | 1.0 |
Recombinant Fusion Proteins/isolation & purification/metabolism | 2 | 2.0 |
Recombinant Proteins/isolation & purification/metabolism | 4 | 2.0 |
*Lectins | 2 | 1.0 |
Kidney Transplantation | 2 | 1.0 |
von Willebrand Factor/analysis/genetics | 2 | 40.0 |
Disulfides/*metabolism | 3 | 13.0 |
Oligodeoxyribonucleotides | 10 | 1.0 |
Vascular Diseases/etiology | 2 | 14.0 |
Endopeptidases/*blood | 3 | 25.0 |
*Diet | 2 | 0.0 |
Drug Resistance | 2 | 0.0 |
Drug Contamination | 3 | 12.0 |
Platelet Membrane Glycoproteins/*immunology | 5 | 17.0 |
Aprotinin/*pharmacology | 4 | 40.0 |
Postoperative Complications/prevention & control | 2 | 6.0 |
Neutrophils/cytology/drug effects | 2 | 25.0 |
Protein Precursors/metabolism | 3 | 2.0 |
Subtilisins/metabolism | 2 | 13.0 |
Arginine/*genetics | 5 | 9.0 |
Cysteine/*genetics | 2 | 7.0 |
Extracellular Matrix/*drug effects | 2 | 33.0 |
von Willebrand Factor/*chemistry/*metabolism/pharmacology | 2 | 100.0 |
Cell Membrane/physiology | 2 | 1.0 |
Gold | 2 | 8.0 |
Blood Grouping and Crossmatching | 3 | 4.0 |
Endothelium/immunology | 3 | 13.0 |
Polyethylene Glycols/*pharmacology | 2 | 7.0 |
Electrophoresis, Agar Gel/methods | 4 | 16.0 |
Purpura, Thrombotic Thrombocytopenic/blood/*therapy | 3 | 100.0 |
Muscle, Smooth, Vascular/*physiology | 2 | 11.0 |
Umbilical Arteries/physiology | 2 | 66.0 |
*Antiplasmin | 3 | 7.0 |
Antigens/*metabolism | 2 | 10.0 |
Myeloproliferative Disorders/*blood | 3 | 33.0 |
*Platelet Count | 2 | 6.0 |
Polycythemia Vera/blood | 2 | 15.0 |
Thrombocythemia, Hemorrhagic/blood | 2 | 28.0 |
von Willebrand Factor/chemistry/isolation & purification/*metabolism | 2 | 100.0 |
Karyotyping | 2 | 0.0 |
Hemagglutination/drug effects | 4 | 50.0 |
Aging/blood | 3 | 5.0 |
Platelet Membrane Glycoproteins/*drug effects | 2 | 66.0 |
Blood Donors | 3 | 1.0 |
von Willebrand Factor/*chemistry/isolation & purification | 3 | 100.0 |
Platelet Membrane Glycoproteins/*analysis/physiology | 2 | 100.0 |
Recombinant Proteins/pharmacokinetics/therapeutic use | 2 | 20.0 |
von Willebrand Disease/blood/*therapy | 4 | 100.0 |
Interleukin-1/*pharmacology | 5 | 1.0 |
Platelet Membrane Glycoproteins/*biosynthesis | 2 | 18.0 |
Desmopressin/*pharmacology/therapeutic use | 2 | 100.0 |
Creatinine/urine | 2 | 1.0 |
von Willebrand Factor/*genetics/immunology | 2 | 66.0 |
Lymphatic Metastasis | 2 | 0.0 |
Endothelium/metabolism | 6 | 11.0 |
von Willebrand Factor/biosynthesis/*physiology | 2 | 100.0 |
von Willebrand Disease/blood/classification | 2 | 100.0 |
Threonine/genetics | 2 | 2.0 |
Mice, Inbred Strains | 2 | 0.0 |
Agglutination | 2 | 11.0 |
Serotonin/metabolism | 2 | 2.0 |
Plasminogen Activators/*blood | 2 | 25.0 |
Desmopressin/administration & dosage/*pharmacology | 6 | 75.0 |
Endothelium, Vascular/drug effects/secretion | 2 | 33.0 |
Fetus | 2 | 0.0 |
Lectins/metabolism | 2 | 2.0 |
Prednisone/therapeutic use | 2 | 1.0 |
Collagen Diseases/*blood | 2 | 50.0 |
Polymers/chemistry | 2 | 8.0 |
Erythrocytes/*cytology | 2 | 10.0 |
Sodium Dodecyl Sulfate | 3 | 5.0 |
Factor VIII/*antagonists & inhibitors/immunology | 3 | 100.0 |
Phosphatidylserines/*metabolism | 2 | 11.0 |
*Databases, Factual | 2 | 3.0 |
Liver Cirrhosis/*blood | 4 | 11.0 |
Autoradiography | 13 | 2.0 |
Protein Processing, Post-Translational/drug effects | 2 | 1.0 |
Arginine | 3 | 3.0 |
Cysteine | 2 | 1.0 |
Video Recording | 2 | 7.0 |
Thrombosis/*blood/etiology | 3 | 33.0 |
Umbilical Arteries | 2 | 11.0 |
Arteries/pathology | 2 | 18.0 |
Infant, Premature/*blood | 2 | 6.0 |
Receptors, Cell Surface/*physiology | 2 | 0.0 |
von Willebrand Factor/analysis/*chemistry | 2 | 100.0 |
Fingers/*blood supply | 2 | 18.0 |
Vibration/*adverse effects | 2 | 20.0 |
Family | 3 | 0.0 |
Thailand | 2 | 1.0 |
Binding, Competitive/physiology | 2 | 6.0 |
Hepatic Veno-Occlusive Disease/etiology | 2 | 100.0 |
Factor VIII/pharmacokinetics/*therapeutic use | 2 | 100.0 |
von Willebrand Factor/pharmacokinetics/*therapeutic use | 2 | 100.0 |
Cyclic AMP/blood | 2 | 5.0 |
Plasma/metabolism | 3 | 18.0 |
*Exons | 2 | 0.0 |
DNA | 2 | 0.0 |
Oligodeoxyribonucleotides/chemistry | 2 | 0.0 |
Glutamine/*genetics | 2 | 11.0 |
Receptors, Thrombin | 8 | 16.0 |
Cycloheximide/pharmacology | 2 | 0.0 |
Genetic Screening | 2 | 0.0 |
Genome, Human | 2 | 0.0 |
Netherlands/epidemiology | 2 | 1.0 |
Factor VIII/analysis/*therapeutic use | 2 | 100.0 |
von Willebrand Disease/complications/*drug therapy | 2 | 100.0 |
Signal Transduction/*physiology | 2 | 0.0 |
Methods | 8 | 3.0 |
Mutation/*physiology | 2 | 1.0 |
von Willebrand Disease/complications/*genetics | 3 | 100.0 |
HLA-DR Antigens/analysis | 2 | 0.0 |
Aurintricarboxylic Acid/*pharmacology | 3 | 33.0 |
Albuminuria/*blood/etiology | 2 | 100.0 |
Antigens/analysis/metabolism | 2 | 50.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 2 | 0.0 |
Dose-Response Relationship, Immunologic | 3 | 0.0 |
Blood Physiology | 2 | 2.0 |
Apyrase/pharmacology | 3 | 42.0 |
Hemophilia A/blood/drug therapy | 2 | 66.0 |
Platelet Membrane Glycoproteins/immunology/*physiology | 4 | 66.0 |
DNA/analysis/genetics | 3 | 2.0 |
DNA Restriction Enzymes | 7 | 1.0 |
*Polymorphism, Restriction Fragment Length | 10 | 1.0 |
von Willebrand Factor/*analysis/genetics | 2 | 100.0 |
Amino Acids/genetics | 2 | 6.0 |
Carbohydrate Conformation | 2 | 1.0 |
Methylation | 3 | 0.0 |
Osteoarthropathy, Primary Hypertrophic/blood/etiology/*immunology | 2 | 100.0 |
Fasting/blood | 3 | 5.0 |
Factor VIII/*physiology | 3 | 75.0 |
Chromosome Deletion | 4 | 0.0 |
Epoprostenol/*biosynthesis | 2 | 8.0 |
*Oligopeptides | 2 | 14.0 |
Peptide Fragments/isolation & purification/metabolism | 5 | 33.0 |
Trypsin/metabolism | 5 | 3.0 |
Blood Specimen Collection | 2 | 4.0 |
Myocardial Infarction/blood/*drug therapy | 2 | 14.0 |
Verapamil/*pharmacology | 2 | 6.0 |
Receptors, Cell Surface/*analysis | 3 | 2.0 |
Antibodies, Monoclonal/physiology | 4 | 5.0 |
Crotalid Venoms/isolation & purification/metabolism/*pharmacology | 2 | 100.0 |
Metalloendopeptidases/pharmacology | 2 | 40.0 |
Codon | 4 | 0.0 |
von Willebrand Disease/blood/complications/*genetics | 3 | 100.0 |
Insulin/*blood | 2 | 1.0 |
Dipyridamole/*pharmacology | 2 | 22.0 |
von Willebrand Factor/isolation & purification/*physiology | 3 | 100.0 |
Erythropoietin/*therapeutic use | 2 | 2.0 |
Plasminogen/*analysis | 2 | 22.0 |
Glycoproteins/*metabolism | 9 | 4.0 |
Protein S | 2 | 3.0 |
Myocardial Infarction/etiology | 2 | 13.0 |
Trypsin | 4 | 2.0 |
Carbohydrates/analysis | 2 | 3.0 |
Glycoside Hydrolases | 2 | 7.0 |
Oligonucleotides/chemistry | 4 | 3.0 |
Oligonucleotide Probes | 5 | 0.0 |
von Willebrand Factor/*genetics/isolation & purification/metabolism | 2 | 100.0 |
Hemolytic-Uremic Syndrome/physiopathology | 2 | 66.0 |
Amino Acids/analysis | 7 | 2.0 |
DNA/*analysis | 2 | 0.0 |
Immunoglobulin M/analysis | 3 | 1.0 |
*Genes, Structural | 6 | 0.0 |
von Willebrand Disease/*blood/physiopathology | 2 | 100.0 |
Chromosomes, Human, Pair 22 | 2 | 1.0 |
Peptide Fragments/isolation & purification | 4 | 7.0 |
Fibronectins/pharmacology | 4 | 8.0 |
Peptide Hydrolases | 4 | 21.0 |
DNA Probes | 2 | 0.0 |
Endothelium, Vascular/*cytology/metabolism/ultrastructure | 2 | 50.0 |
*Enzyme-Linked Immunosorbent Assay | 4 | 5.0 |
Leptin/*blood | 2 | 2.0 |
Thrombophilia/blood | 2 | 25.0 |
Snakes | 2 | 22.0 |
Fibrinogen/*pharmacology | 2 | 50.0 |
Factor VIII/isolation & purification/*metabolism | 4 | 66.0 |
Blood Coagulation Factors/analysis/*drug effects | 2 | 66.0 |
von Willebrand Disease/drug therapy | 4 | 100.0 |
Membranes, Artificial | 4 | 4.0 |
Gels | 2 | 2.0 |
Serine Endopeptidases/pharmacology | 2 | 20.0 |
Trypsin/pharmacology | 5 | 3.0 |
Kidney Failure, Chronic/*blood | 5 | 7.0 |
Vascular Endothelial Growth Factor Receptor-1/blood | 2 | 50.0 |
Oligopeptides/*pharmacology | 2 | 2.0 |
Absorption | 2 | 1.0 |
Thrombocytopenia/*blood | 2 | 14.0 |
*Pregnancy Complications, Hematologic | 3 | 30.0 |
*Twins | 2 | 7.0 |
*Twins, Monozygotic | 2 | 11.0 |
Platelet Factor 4/metabolism | 2 | 3.0 |
*Cold | 2 | 3.0 |
*Splenectomy | 2 | 6.0 |
Factor VIII/metabolism/*therapeutic use | 2 | 100.0 |
Muscle, Smooth, Vascular/cytology | 2 | 6.0 |
Antibodies, Monoclonal/*diagnostic use | 6 | 2.0 |
Calpain/*pharmacology | 2 | 100.0 |
Equipment Design | 2 | 1.0 |
Fixatives/pharmacology | 2 | 18.0 |
Formaldehyde/pharmacology | 3 | 10.0 |
Hemagglutination | 2 | 5.0 |
Randomized Controlled Trials | 3 | 0.0 |
Plasminogen Activators/analysis | 2 | 25.0 |
Factor VIII/*antagonists & inhibitors | 3 | 60.0 |
Endothelium, Vascular/*analysis/secretion | 2 | 100.0 |
von Willebrand Factor/*analysis/antagonists & inhibitors | 2 | 100.0 |
Blood Platelets/*analysis | 2 | 11.0 |
Ristocetin/*blood | 2 | 100.0 |
Liver Diseases/*blood | 3 | 9.0 |
*Asialoglycoproteins | 4 | 50.0 |
Fibronectins/*analysis | 2 | 9.0 |
Endothelium, Vascular/*analysis | 2 | 100.0 |
Factor VIII/*analysis/immunology | 4 | 100.0 |
Fibrinogen/*therapeutic use | 2 | 40.0 |
Hemophilia A/*drug therapy | 2 | 40.0 |
von Willebrand Disease/classification/*diagnosis/genetics | 2 | 100.0 |
Adenosine Diphosphate/physiology | 2 | 28.0 |
Isoflurophate/pharmacology | 2 | 8.0 |
*Cloning, Molecular | 3 | 0.0 |
Blood Platelet Disorders/*blood | 3 | 33.0 |
Immunoglobulin E/analysis | 2 | 3.0 |
*Factor VIII | 2 | 66.0 |
Diabetes Mellitus/blood | 2 | 2.0 |
Plasminogen Inactivators | 2 | 13.0 |
Ristocetin/diagnostic use | 2 | 66.0 |
Hemolytic-Uremic Syndrome/*blood/therapy | 2 | 100.0 |
von Willebrand Factor/*blood/isolation & purification | 2 | 100.0 |
Immune Sera | 4 | 1.0 |
Thrombin/*physiology | 2 | 9.0 |
Microbial Collagenase | 2 | 40.0 |
Arachidonic Acid | 2 | 3.0 |
Arachidonic Acids/metabolism | 2 | 5.0 |
Chromatography, Thin Layer | 3 | 1.0 |
Glycoproteins/*physiology | 3 | 5.0 |
Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase | 2 | 6.0 |
Glycoproteins/physiology | 3 | 10.0 |
Factor VIII/analysis/immunology | 6 | 50.0 |
von Willebrand Disease/*complications | 2 | 66.0 |
Factor VIII/immunology/*isolation & purification | 3 | 100.0 |
*Immunosorbent Techniques | 2 | 11.0 |
Thermodynamics | 2 | 0.0 |
Stroke Volume | 2 | 3.0 |
Drugs, Chinese Herbal/*therapeutic use | 2 | 2.0 |
Glycoproteins/*blood | 2 | 2.0 |
*Exertion | 3 | 1.0 |
Blood Platelets/analysis | 7 | 43.0 |
Ristocetin/*metabolism | 2 | 100.0 |
Prolactin/blood | 2 | 0.0 |
Anoxia/*blood | 2 | 13.0 |
Lectins/pharmacology | 2 | 5.0 |
Argipressin/*blood | 2 | 0.0 |
Angina, Unstable/blood/*drug therapy | 2 | 50.0 |
*Chromosome Mapping | 2 | 0.0 |
*Antibodies | 2 | 4.0 |
Desmopressin/*adverse effects/therapeutic use | 2 | 100.0 |
Blood Platelets | 2 | 8.0 |
von Willebrand Factor/*blood | 2 | 100.0 |
DNA, Recombinant | 4 | 2.0 |
RNA, Messenger/*analysis | 2 | 0.0 |
Depression, Chemical | 2 | 1.0 |
Cardiovascular Diseases/etiology | 3 | 6.0 |
Glutamates | 2 | 18.0 |
Valine | 2 | 3.0 |
Organoids/metabolism | 2 | 50.0 |
*Chromosome Deletion | 2 | 0.0 |
von Willebrand Disease/*genetics/immunology | 2 | 100.0 |
Antigen-Antibody Complex | 3 | 1.0 |
Indicators and Reagents | 2 | 0.0 |
Factor VIII/analysis/*immunology | 3 | 37.0 |
Desmopressin/administration & dosage/adverse effects/*therapeutic use | 2 | 100.0 |
Freeze Drying | 3 | 13.0 |
Blood Platelets/immunology/*physiology | 2 | 28.0 |
von Willebrand Factor/*analysis/biosynthesis/immunology | 2 | 100.0 |
Glycine | 2 | 2.0 |
Starch/*analogs & derivatives | 2 | 50.0 |
Adenosine Diphosphate/blood | 2 | 25.0 |
6-Ketoprostaglandin F1 alpha/analysis | 2 | 66.0 |
Collodion | 2 | 5.0 |
Myeloma Proteins/*immunology | 2 | 50.0 |
Diabetic Retinopathy/*pathology | 2 | 66.0 |
Lysine | 2 | 4.0 |
Plasmin/*metabolism | 4 | 15.0 |
Anti-Inflammatory Agents, Non-Steroidal/adverse effects | 2 | 28.0 |
Intraoperative Period | 2 | 3.0 |
Uremia/drug therapy | 2 | 100.0 |
*Serine Endopeptidases | 4 | 11.0 |
Intercellular Signaling Peptides and Proteins/blood | 3 | 11.0 |
Endopeptidases/*metabolism | 2 | 1.0 |
Gold/diagnostic use | 3 | 23.0 |
DNA/*metabolism | 2 | 0.0 |
Transglutaminases | 2 | 25.0 |
Blood Platelets/*analysis/ultrastructure | 2 | 66.0 |
Factor XIII/*analysis | 2 | 40.0 |
Cyanogen Bromide | 2 | 3.0 |
Membrane Proteins/*metabolism | 3 | 0.0 |
Area Under Curve | 2 | 0.0 |
Tachyphylaxis | 2 | 22.0 |
Sodium Dodecyl Sulfate/diagnostic use | 2 | 50.0 |
Megakaryocytes/*analysis | 3 | 75.0 |
Glycoproteins/immunology/*metabolism | 3 | 16.0 |
Membrane Proteins/immunology/*metabolism | 2 | 7.0 |
Protein C | 2 | 10.0 |
Blood Coagulation Factors/*immunology | 4 | 57.0 |
Plasmin/pharmacology | 2 | 11.0 |
Streptokinase/pharmacology | 3 | 37.0 |
Mercaptoethanol/pharmacology | 2 | 6.0 |
*Blood Coagulation Factors | 3 | 10.0 |
Blood Coagulation Factors/*genetics | 3 | 33.0 |
Hemostatics/*pharmacology | 2 | 15.0 |
Coronary Disease/blood | 2 | 7.0 |
Goats/immunology | 2 | 9.0 |
Blood Coagulation Factors/*pharmacology | 2 | 40.0 |
Blood Coagulation Factors/*isolation & purification | 2 | 50.0 |
Fibronectins/*blood | 2 | 7.0 |
Thrombocytopenia/blood | 2 | 20.0 |
Hybridomas/*immunology | 2 | 6.0 |
Prostaglandins E/pharmacology | 2 | 7.0 |
Blood Coagulation Factors/*analysis/isolation & purification/standards | 2 | 100.0 |
Counterimmunoelectrophoresis | 3 | 13.0 |
Factor VIII/*analysis/isolation & purification/standards | 2 | 100.0 |
Fibrinogen/*administration & dosage | 2 | 28.0 |
Blood Platelets/*physiopathology | 2 | 50.0 |
Swine/blood | 2 | 40.0 |
Chymotrypsin/pharmacology | 3 | 15.0 |
Peptide Hydrolases/*pharmacology | 2 | 40.0 |
*Blood Platelets | 2 | 9.0 |
Peptides | 2 | 3.0 |
Egtazic Acid/*analogs & derivatives/pharmacology | 2 | 8.0 |
Lipoproteins, HDL Cholesterol/blood/drug effects | 2 | 25.0 |
Lipoproteins, LDL Cholesterol/blood/drug effects | 2 | 15.0 |
von Willebrand Factor/*analysis/drug effects | 3 | 100.0 |
Angiotensin-Converting Enzyme Inhibitors/*therapeutic use | 2 | 0.0 |
Isoquinolines/*therapeutic use | 2 | 18.0 |
*Gene Expression Profiling | 2 | 0.0 |
Postoperative Hemorrhage/prevention & control | 2 | 100.0 |
Intercellular Signaling Peptides and Proteins/*blood | 2 | 3.0 |
Blood Loss, Surgical/prevention & control | 2 | 25.0 |
Endothelium, Vascular/*drug effects/*physiology | 2 | 40.0 |
